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Abstract 
Breast cancer is the most commonly diagnosed cancer in Australian women, with advances in 
detection and treatment of breast cancer there is a current overall five-year survival rate of 
approximately 90%. For some individual breast cancer survivors, survival is associated with 
psychological and physiological stressors that can negatively affect well-being and quality of 
life as well as have a further adverse impact on long-term survival. These stressors can affect 
the body’s physiological stress response system, causing allostatic load (AL) and 
dysregulations that may be associated with symptoms such as fatigue, depression, anxiety, 
hypertension, and inflammation. AL is a multisystem approach to measure the cumulative 
negative effects that stress has on the body’s systems and overall health. Psychological and 
physiological stress is also associated with accelerated cellular aging and chromosome 
instability caused by telomere attrition. These cellular deficits can lead to an increased risk 
for the development of other diseases such as cardiovascular disease, diabetes and cancer 
recurrence.  
Recent research has provided evidence that mindfulness-based psychological interventions 
that have been developed to meet the needs of breast cancer survivors can improve their 
psychological well-being and quality of life. Furthermore, other research has demonstrated 
that these interventions can lead to a reduction in physiological stress biomarkers. 
Physiological stress biomarkers indicate the activity of the stress response system, therefore 
a reduction subsequent to participation in a psychological intervention may indicate clinical 
health benefits.  
The aim of this pilot study was to examine the effects of Acceptance and Commitment 
Therapy (ACT), a psychological treatment that incorporates acceptance and mindfulness 
strategies, on physiological and molecular biomarkers of stress and AL in breast cancer 
survivors. Breast cancer survivors, who had completed primary breast cancer treatment in 
the previous two years, were randomly allocated into three groups. Two groups attended 
ninety minutes of either a group-based ACT (Group 1) or Breast Cancer Education (BCE) 
program (Group 2) for six weeks; these two groups then crossed-over to the other 
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intervention for a further six weeks. The third group (Group 3) was waitlisted for the first six 
weeks and then attended the ACT program for the subsequent six weeks. Physiological and 
molecular biomarkers of stress: heart rate, blood pressure, fasting blood glucose, telomere 
length, interleukin-6, cortisol and salivary alpha-amylase, were assessed before and after 
each intervention or wait-list, with a fourth measurement time point at six months after 
completion of the interventions. Six of these biomarkers were used to calculate the change 
in AL for each participant in response to the ACT intervention.  
The study identified a significant reduction in cumulative allostatic load in Group 3 
participants following the ACT intervention, but AL was increased in Groups 1 and 2. The study 
did not identify a statistically significant reduction in any individual biomarker from pre- to 
post-6 week ACT intervention for any group however, a reduction in blood pressure in Group 
1 participants after 12 weeks (ACT and BCE) was evident. These results suggest that the 
current ACT intervention could drive improvements in AL, but the effects are highly variable. 
It may be that a longer intervention is required before a change in physiological and molecular 
biomarkers becomes measurable. Alternatively, it is plausible that the majority of participants 
in this study were not under substantial stress at the beginning of the trial and therefore their 
stress biomarkers were not elevated and had no potential to improve. A future trial could 
specifically recruit participants with elevated stress biomarkers. 
Keywords 
Allostasis, allostatic load, acceptance and commitment therapy, stress biomarkers, relative 
telomere length, salivary cortisol, salivary alpha-amylase, cytokines, interleukin-6.  
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Chapter 1: Introduction and literature review 
1.1 Breast cancer survivorship 
Breast cancer is the most commonly diagnosed cancer in Australian women and was the 
second most commonly diagnosed cancer in Australia in 2014 (Australian Institute of Health 
and Welfare (AIHW) 2017). There were 16,753 new cases of breast cancer in Australia in 2014 
(140 men and 16,613 women),  with one in eight Australian women diagnosed with breast 
cancer by the age of 85 years (AIHW 2017). Due to advances in cancer treatments and 
increased rates of early detection, the overall five-year survival rate for breast cancer has 
increased to 90% (AIHW 2017). It is predicted that there will be 18,235 new breast cancer 
cases in 2018 (AIHW 2017) and therefore, over 16,000 new breast cancer survivors in 2018.  
Despite the high survival rates, breast cancer is a stressful experience (McGregor & Antoni 
2009), with breast cancer diagnosis, treatment and survivorship found to be associated with 
a complex array of stressors, all of which can impact survivor’s wellbeing and quality of life 
(QoL). The extent to which these stressors are experienced by the individual breast cancer 
survivor will vary due to individual characteristics such as age, stage of cancer, treatment 
modality, social support and coping ability (Boyes et al. 2009). 
The early or extended survivorship period is defined as the period from completion of primary 
treatments (including surgery, radiotherapy and chemotherapy), to up to five years after 
completion of treatment (Boyes et al. 2009). This period of survivorship is a vulnerable phase 
in which survivors may face multiple physiological and psychological issues (Cheng et al. 
2014). 
Physiological issues may be treatment-related, including persistent and/or late emerging 
symptoms such as fatigue, sleep disturbance, physical function decline, pain, lymphoedema, 
peripheral neuropathy (Alfano et al. 2016; Cheng et al. 2016), vasomotor complaints including 
hot flushes and cold sweats (Fallowfield & Jenkins 2015), sexual dysfunction, early onset 
menopause and infertility (Boyes et al. 2009). Although not life threatening, these 
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consequences of treatment may compromise daily activities and ability to return to pre-
cancer life, potentially negatively affecting individual survivors overall sense of well-being and 
QoL (Cheng et al. 2016).  
Breast cancer survivors often report experiencing psychological symptoms such as emotional 
distress and mood disturbance including depression and anxiety (Matchim et al. 2011; 
Starkweather et al. 2013). These psychological issues may continue from the stress 
experienced during diagnosis and treatment of breast cancer or they may arise due to new 
issues in the survivorship period. Breast cancer survivors may experience anxiety about the 
transition from active treatment and their return to a ‘new normal’ lifestyle (Boyes et al. 
2009). Breast cancer survivors may also experience stress associated with survivorship guilt, 
loneliness, concerns about burdening loved ones and uncertainty about the future. A 
common psychological issue in breast cancer survivors is fear of cancer recurrence (FCR) and, 
it is reported that half of all cancer survivors experience FRC (Rouleau et al. 2015). There are 
many potential sources of increased stress in breast cancer survivors, and increased stress 
can be associated with lower QoL (Custers et al. 2017).  
 
1.2 The human stress response, allostasis and allostatic load 
The human body responds to stressors (physiological and/or psychological) by activating the 
physiological stress response system. The physiological stress response is complex and tightly 
regulated. It involves multiple systems and pathways that interact to produce physiological 
adaptations that improve the chance of survival when faced with stressors (Smith & Vale 
2006). The initial responses are referred to as ‘fight or flight’ responses and include increased 
awareness and cognition, increased heart and respiratory rates, as well as the inhibition of 
general functions such as feeding, digestion, reproduction and growth (Smith & Vale 2006). 
Once the stressor is removed, the stress response systems attempt to return to basal 
functioning states, thus restoring balance and homeostasis (Sturmberg et al. 2017). 
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The major systems involved in the stress response include the sympathetic nervous system 
(SNS), the hypothalamic-pituitary-adrenal (HPA) axis, and the immune system. These systems 
are mediated by a complex network of bidirectional feedback signals (Figure 1), in which 
activation or suppression of one component of the system stimulates or suppresses other 
components of the system (Glaser & Kiecolt-Glaser 2005; Reiche et al. 2004). 
 
Figure 1: Stress response system network of bidirectional communication between the SNS, 
HPA axis and immune systems. Modified from Reiche et al. 2004 
                                
Optimal functioning of the stress response system after exposure to a stressor requires 
successful coordination and adaptation of all three major systems to maintain healthy 
functioning and homeostasis (Glaser & Kiecolt-Glaser 2005; Sturmberg et al. 2017). The 
dynamic and adaptive regulatory process that maintains homeostasis during exposure to 
stressors is defined as allostasis (McEwen 2000; McEwen 2017; McEwen & Gianaros 2010; 
 SNS HPA 
Axis 
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Streeter et al. 2012). Stress response and allostasis are protective in the short-term, but long-
term activation and adaptation of the stress response systems results in allostatic 
load/overload (AL), potentially causing cumulative ‘wear and tear’ on the body’s systems 
(Figure 2) (McEwen 2000). AL and the associated wear and tear, damages components of the 
stress response systems leading to dysregulations that can result in either inadequate or 
overactive activity (Gallo et al. 2014; Wan et al. 2016).  Dysregulations can lead to 
hypertension, fatigue, anxiety, depression, sleep disturbance, cognitive functional decline 
(Sturmberg et al. 2017) and ultimately increased cellular aging and the risk of disease (Epel 
2009; McEwen 2017). 
 
Figure 2: Model of allostasis and allostatic load (McEwen 2000). 
 
1.2.1 The sympathetic nervous system (SNS) 
The brain, via the central nervous system (CNS), perceives psychological and physiological 
stressors (Streeter et al. 2012), and controls how the body responds to the stressor. 
Interpretation of the stressor as a threat results in the suppression of the calming, 
parasympathetic nervous system (PSNS) and stimulation of the activating, sympathetic 
nervous system (SNS). Stimulation of the SNS occurs immediately following the stressor and 
results in the rapid release of catecholamines (noradrenaline and adrenaline), from the 
adrenal medulla (Ali & Pruessner 2012; Sturmberg et al. 2017), inducing the initial fight or 
flight responses (Hulett & Armer 2016). These responses include elevated heart rate, 
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increased blood pressure, and increased respiratory rate (Ali & Pruessner 2012), all of which 
aim to promote survival in the instance of a threat. Increased SNS activity is beneficial in the 
short term for survival, but sustained high SNS activity may incur negative effects such as 
anxiety, hypertension, inflammation and cardiovascular disease (QoL) (Raison & Miller 2003; 
Streeter et al. 2012). 
1.2.2 The hypothalamic-pituitary-adrenal (HPA) axis  
The HPA axis is the major endocrine axis that regulates circulating concentrations of the 
primary stress mediator, cortisol. Cortisol, is a hormone secreted from the adrenal cortex via 
multiple negative feedback loops (Figure 3) (Spiga et al. 2011). Circulatory cortisol 
concentrations follow diurnal circadian rhythms of secretion, with a peak blood concentration 
in the morning (half an hour to an hour after waking), followed by a steady decline over the 
course of the day (Matousek et al. 2011; O’Leary et al. 2016). Under basal non-stressed 
conditions, cortisol functions to maintain blood glucose concentrations, thus providing energy 
for the actively functioning brain and muscular system (Hannibal & Bishop 2014). In addition 
to the diurnal rhythm, the activity of the HPA axis increases as a response to stress to promote 
survival and avoid danger (Hannibal & Bishop 2014).   
 
Figure 3: Hypothalamic-pituitary-adrenal (HPA) axis (Spiga et al. 2011). 
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The perception of a stressor (physical or psychological), activates neural pathways that induce 
the release of corticotropin releasing hormone (CRH) from the paraventricular nucleus (PVN) 
in the hypothalamus (Figure 3). CRH is carried by the portal system to the anterior pituitary 
gland, stimulating the release of adrenocorticotropin hormone (ACTH) into the circulatory 
system. ACTH binds to receptors in the adrenal cortex, stimulating the production and 
secretion of cortisol (O’Leary et al. 2016; Ryan et al. 2007; Streeter et al. 2012). Systemic 
cortisol concentration rises, to nearly double the basal concentration, approximately 15 
minutes after the onset of stress and can remain elevated for several hours (Hannibal & 
Bishop 2014). The increased concentration of cortisol mobilises stored glucose to provide the 
extra energy needed to maintain the flight or fight responses. Elevated cortisol also conserves 
energy usage through suppressing  non-vital organ systems thus increasing the energy 
available for the stress response (Hannibal & Bishop 2014). 
Elevated concentrations of cortisol regulate the stress response by negative feedback loops 
to both the hypothalamus and the pituitary gland, decreasing the production of both CRH and 
ACTH (Spiga et al. 2011). These negative feedback mechanisms adapt to the elevated 
concentrations of cortisol (allostasis) in order to maintaining homeostasis within the HPA axis. 
Once the stressor is removed, the decreased neural stimulation as well as the negative 
feedback loops return the HPA axis and cortisol concentration to homeostatic functioning 
states (Spiga et al. 2011). 
Chronic stress, either continuous or repetitive, can cause chronic activation or reactivation of 
the HPA axis, and continuous high concentrations or repeated surges of cortisol. This can lead 
to AL in the HPA axis and can result in HPA axis dysregulation and dysfunction (Hannibal & 
Bishop 2014; O’Leary et al. 2016). The resultant cortisol dysregulation may vary due to 
individual characteristics such as age, sex, genetics, type of stressor, individual perception of 
stress and coping abilities (Sturmberg et al. 2017). 
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Dysregulations in the HPA axis and cortisol functioning have been found to be associated with 
symptoms such as fatigue (Jain 2012) and sleep disturbances (Ryan et al. 2007). Cortisol plays 
important roles in the regulation of both the SNS and immune systems and as such 
dysregulation in the HPA axis may affect these systems and result in symptoms such as 
anxiety, hypertension and inflammation and therefore increase the risk of disease and reduce 
QoL (Sturmberg et al. 2017). 
1.2.3 The immune system 
The immune system is also an extremely complex system, principally functioning as the 
human body’s defence against threats, including pathogens (such as bacteria, virus and fungi) 
and tissue injury (Luecken & Compas 2002). The immune system is comprised of organs, 
vessel systems, individual cells, and signalling proteins. The primary immune organs include 
the bone marrow and the thymus, where immune system cells such as lymphocytes are 
produced and matured. The secondary immune organs include the lymph nodes, tonsils, and 
the spleen; these are the locations in which the lymphocytes function to defend against 
pathogens.  
There are two arms of the immune system, innate and adaptive, the initial immune response 
to stressors occurs by the activation of the innate immune system. This component of the 
immune system is a non-specific, first line of defence that relies on a number of different 
types of immune cells including monocytes, macrophages, and neutrophils (Seruga et al. 
2008). These immune cells are constantly in circulation and become activated when surface 
receptors come in contact with a range of molecules including pathological agents and 
endogenous molecules (Seruga et al. 2008). Activation of receptors on immune cells leads to 
the production of cytokines, which facilitate the inflammatory response (Seruga et al. 2008). 
The inflammatory response attempts to protect and defend the body against any threat to its 
integrity and homeostasis (Halaris 2015). This occurs by complex interactions between the 
activated cells and signalling molecules, resulting in the mobilisation of more immune cells, 
with a goal to control and eliminate the pathological agent and to enable tissue repair and 
regeneration (Halaris 2015). While the inflammatory response in the short-term is beneficial 
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and protective, longer-term or excessive activation can cause AL and dysregulations that can 
result in tissue damage and induce inflammatory associated diseases such as atherosclerosis, 
diabetes, neurodegeneration and cancer (Halaris 2015; Irwin & Cole 2011). 
Cytokines, mediators of the immune system, are small soluble glycoproteins that have 
multiple functions including the promotion of growth, differentiation and activation of 
immune cells (Seruga et al. 2008). Cytokines can either have pro- or anti-inflammatory activity 
depending on the microenvironment. Under homeostatic conditions the inflammatory 
response is regulated by multiple active mechanisms that maintain a balance between pro- 
and anti-inflammatory cytokines (Seruga et al. 2008), when the balance is not maintained 
chronic immune activation and inflammation can occur.  
The immune system is not only activated by pathological agents but may also be activated by 
psychological stress via the HPA axis and the SNS (Bower et al. 2014; Irwin & Cole 2011). Stress 
activates the HPA axis and SNS, and the primary mediators of these systems (cortisol and 
catecholamines), then alter the function of immune organs and cells (Maier & Watkins 1998). 
The complex interaction between these three systems involves bidirectional feedback (Figure 
4) (Glaser & Kiecolt-Glaser 2005), and the resulting neuro-immune circuits coordinates the 
immune response with the fight or flight response maximising the overall chance of survival 
(Irwin & Cole 2011). Chronic stress can dysregulate the immune response by affecting the 
interplay between the three major stress response systems (Glaser & Kiecolt-Glaser 2005).         
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The SNS regulates the immune system via the release of adrenaline from the adrenal medulla 
into systemic circulation. Immune cells have receptors for adrenaline, and so circulating 
adrenaline activates immune cells to increase production of proinflammatory cytokines (Irwin 
& Cole 2011). The SNS also directly innervates immune sites such as the lymph nodes, thus 
directly delivering noradrenaline and further increasing the production of proinflammatory 
cytokines (Glaser & Kiecolt-Glaser 2005; Irwin & Cole 2011). Chronic stress and continued 
activation of the SNS results in increased production of proinflammatory cytokines.      
Figure 4: The stress response system. Activation of immune system via SNS and HPA axis. 
Bidirectional communication between immune system, SNS and HPA axis. Modified from 
Glaser & Kiecolt-Glaser 2005. 
In addition to its role as a stress hormone, cortisol is a potent anti-inflammatory hormone, 
functioning to supress the production of proinflammatory cytokines (Irwin & Cole 2011). 
Cortisol also assists in returning the inflammatory response to homeostasis after cessation of 
a stressor (Raison & Miller 2003). Chronic stress and the associated dysregulation in the HPA 
axis and cortisol function, may result in increased production of proinflammatory cytokines 
and tissue inflammation (Seruga et al. 2008).  
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The bidirectional relationship between the immune system and both the SNS and the HPA 
axis means that the SNS and HPA axis influence the immune system and the immune system 
also has effects on these systems (Raison & Miller 2003). The increased production of 
proinflammatory cytokines in response to stress triggers a cluster of behavioural symptoms 
known as ‘cytokine induced sickness behaviour’ (McGregor & Antoni 2009). Symptoms 
include fatigue, sleep disturbance, reduced cognition and depression (Bower et al. 2011; 
Halaris 2015; Seruga et al. 2008). This cluster of symptoms is found to be associated with poor 
QoL in breast cancer survivors (Bower et al. 2011), and has also been linked to the early onset 
of age-related diseases and conditions including CVD, osteoporosis, arthritis, diabetes, frailty 
and functional decline and some cancers (Bower et al. 2014; Glaser & Kiecolt-Glaser 2005). 
 
1.3 Biomarkers of stress 
The finding that psychological stress is associated with alterations in the SNS, HPA axis and 
immune systems has led to the use of biological variables within these systems as possible 
biomarkers of stress and therefore QoL. Biomarkers are predominantly measured in blood 
samples, but recently saliva has been investigated as an alternative and less invasive source 
of biomarkers (Lipschitz et al. 2013).  
1.3.1 Cortisol 
Cortisol has been extensively studied and utilised as a biomarker of stress, anxiety and 
depression (Levine et al. 2007; O’Leary et al. 2016). Cortisol is measured in blood, urine and 
saliva. In blood,  cortisol exists in two forms, bound and free (Levine et al. 2007). The bound 
form is described as the non-active form, with approximately 95% of cortisol being bound to 
proteins such as albumin and corticosteroid-binding globulin (Bozovic et al. 2013). The 
remaining 5% is the free, biologically active form (Bozovic et al. 2013). Measuring blood 
cortisol concentrations has been the most commonly used method in assessing cortisol but 
this method measures both free and bound forms. The stress from the procedure itself can 
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induce a stress response and therefore alter cortisol concentration, giving false results 
(Bozovic et al. 2013). Due to these shortcomings there is increased interest in the utilisation 
of salivary cortisol as a surrogate measure of free cortisol (Levine et al. 2007). Cortisol enters 
saliva via diffusion through the salivary glands, with the concentration of cortisol in saliva 
accounting for 70% of the free non-bound blood cortisol (Bozovic et al. 2013). The 
measurement of salivary cortisol is a minimally invasive method, therefore should not induce 
a stress response.  
1.3.2 Salivary alpha-amylase 
Methods for assessing SNS activity vary and include cardiovascular measures such as heart 
rate, blood pressure and urinary catecholamine concentrations (Ali & Pruessner 2012). 
Salivary alpha-amylase (sAA) concentration is also associated with SNS activity and has been 
used as a biomarker for the SNS component of the body’s stress response (Ali & Pruessner 
2012; Nater & Rohleder 2009; Wan et al. 2016). SAA is a digestive enzyme, secreted by the 
oral cavity that functions to assist in the breakdown of starch molecules from food. While sAA 
is not a direct by-product of the SNS, it has been found that physical and psychological stress 
conditions are associated with elevated concentrations of sAA (Ali & Pruessner 2012). sAA 
concentrations have also been found to be positively associated with overall changes in 
noradrenaline in response to stress (Ali & Pruessner 2012). Stress hormones of the SNS, 
catecholamines, are not found in saliva in reliable qualities but the association between SNS 
activity and sAA concentrations has led to the use of sAA  as a minimally invasive surrogate 
measure of SNS activity (Holt-Lunstad et al. 2008; Lipschitz et al. 2013). 
1.3.3 Proinflammatory cytokines 
The similarities between cytokine-induced sickness behaviour and symptoms experienced by 
breast cancer survivors led to the investigation of mediators of the immune system as possible 
inflammatory biomarkers of stress (Miaskowski & Aouizerat 2012). Serum cytokines as well 
as downstream markers of cytokines are the most common inflammatory proteins that have 
been investigated (Miaskowski & Aouizerat 2012). The current method for measuring 
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inflammatory biomarkers is via blood specimens (Slavish et al. 2015) and further investigation 
is needed to identify possible inflammatory biomarkers in non-invasive samples such as saliva. 
Stress is associated with immune activation and the release of proinflammatory cytokines, 
such as tumour necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1β (IL-1β) (Glaser & 
Kiecolt-Glaser 2005). These cytokines have been found to be elevated in breast cancer 
survivors with persistent fatigue (Barsevick et al. 2010). Concentrations of IL-1β and IL-6 have 
also been found to be positively associated with depressive symptoms (Law et al. 2016; 
Miaskowski & Aouizerat 2012; Slavish et al. 2015). Downstream markers of proinflammatory 
cytokines have also been measured as stress biomarkers as they are hypothesised to reflect 
cytokine activity (Bower et al. 2014). Higher concentrations of soluble TNF receptor type II 
(sTNF-RII), a marker of TNF activity, and IL-1 receptor antagonist (IL-1Ra), a marker of IL-1β 
activity have been identified in fatigued individuals compared to non-fatigued individuals 
(Miaskowski & Aouizerat 2012). The links between concentrations of proinflammatory 
cytokines, TNF, IL-1β and IL-6, and stress-related symptoms such as fatigue and depression 
has identified that these cytokines may be possible biomarkers of stress. 
1.3.4 Telomere length 
Chromosomal telomere length in peripheral blood mononuclear cells (PBMC) is an emerging 
biomarker of stress, aging and QoL. Telomeres are non-coding DNA sequences, consisting of 
a simple repeat sequence (TTAGG) that caps the ends of chromosomes (Epel et al. 2006). They 
promote chromosomal stability by preventing the loss of genetic information and protecting 
chromosomes from fusing together during cellular division; these processes can lead to 
cancer processes (Starkweather et al. 2013). 
Regulation of telomere length is a complex interplay between the mechanisms of telomere 
attrition and elongation (Nersisyan 2016). Telomeres naturally shorten with each cell division, 
resulting in a gradual decline of telomere length over time, with older cells tending to have 
shorter telomeres compared to younger cells (Epel 2009; Starkweather et al. 2013). Telomere 
shortening is therefore a marker of cellular aging (Epel 2009). Critically short telomeres signal 
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the cell to stop dividing and enter cellular senescence (Biegler et al. 2012). Telomere 
shortening and cellular senescence is thought to be an indicator of bodily aging (Epel et al. 
2009). Short telomeres in PBMCs have been found to be associated with increased risk factors 
for age-related diseases, such as, atherosclerosis, hypertension, obesity, diabetes and cancer 
(Biegler et al. 2012; Epel et al. 2009; Epel 2009). Telomere length may also predict cancer 
survival and cancer recurrence, as well as early mortality (Biegler et al. 2012; Duggan et al. 
2014; Erdmann et al. 2017). 
The primary mechanism of telomere length maintenance and elongation, is dependent on the 
expression of telomerase, an enzyme that functions by adding telomeric DNA to shortened 
telomeres  (Epel 2009; Nersisyan 2016). Telomerase promotes cell longevity by slowing 
telomere shortening and therefore stopping the activation of senescence. Thus, the 
interaction between short telomeres and telomerase appears to affect the risk of cell death 
and therefore bodily aging (Epel et al. 2009). 
Long-term exposure to stress and the resultant AL appears to be associated with impaired 
telomere maintenance having effects on both telomere length and telomerase activity (Law 
et al. 2016; Tomiyama et al. 2012).  While the exact mechanisms in which stress affects 
telomere length are complicated and not fully understood, it has been identified that 
increases in stress response mediators such as cortisol, adrenaline, IL-6 and TNF are 
associated with accelerated telomere shortening and dampened telomerase activity in 
PBMCs (Epel 2009; Law et al. 2016; Tomiyama et al. 2012). The identification of the links 
between stress and telomere length has led to the measurement of telomere length in PBMCs 
as a biomarker of stress. 
1.3.5 Allostatic load as a cumulative measure of stress 
As the stress response and allostasis affects many physiological systems leading to AL, it is 
postulated that a cumulative, multisystem AL measure may have greater value in the 
assessment of stress and the associated biological burden than individual biomarkers. 
Extensive research into the human body’s physiological responses to stress has linked 
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individual regulatory systems to health risks, yet little attention has been paid to the co-
occurrence of physiological dysregulations across multiple systems (Seeman et al. 2010). The 
measure of AL by a composite score or index aims to address this limitation. AL has been 
proposed as a conceptualisation of cumulative biological burden that could signal early signs 
of dysregulations across multiple physiological systems (Seeman et al. 2001). 
Allostasis and AL is proposed to occur in three stages; beginning with the initial, primary stage 
which is associated with acute stress and primary mediators of multiple physiological systems 
(McEwen 2003). Continued activation of primary mediators leads to primary effects (anxiety, 
sleep problems and mood changes). Primary effects and continued response to primary 
mediators can lead to secondary outcomes or dysregulations in multiple systems including 
the metabolic, cardiovascular and immune systems. The final stage is associated with tertiary 
outcomes including CVD, depression, cognitive decline, fatigue, cellular aging, cancer and 
ultimately mortality (Juster et al. 2010; Mauss et al. 2015). 
The Allostatic Load Index (ALI), first developed in 1997 by Seeman and colleagues, aimed to 
provide an assessment of the cumulative multisystem AL associated with stress and ageing. 
There have been many different approaches to developing an ALI to measure allostatic load, 
with all approaches aiming to create a composite score based on indicators (biomarkers) from 
multiple systems associated with mediators, effects and outcomes of allostasis and AL (Beckie 
2012). The initial ALI measure utilised 10 biomarkers (Seeman et al. 1997). Four of the 
biomarkers were primary mediators of AL that are secreted by the adrenal glands: cortisol, 
adrenalin, noradrenalin and dehydroepiandrosterone sulphate (DHEAS) (Figure 5). The 
remaining six biomarkers were measures of secondary outcomes of allostatic load: systolic 
and diastolic blood pressure, waist-hip ratio, high-density lipoprotein, total cholesterol and 
glycosylated haemoglobin (Figure 5). These original 10 measures were chosen by Seeman et 
al. (1997) as they covered both primary mediators and secondary outcomes of allostatic load, 
they also included multiple systems associated with allostasis. This measure of allostatic load 
has formed the foundation for many subsequent studies utilising an ALI but there is a large 
variation in the specific methods used to calculate ALI among these published studies. These 
variations in ALI calculation include the difference in the number and range of biomarkers 
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utilised (Beckie 2012; Juster et al. 2010). Read and Grundy (2012) summarised the different 
biomarkers that have been incorporated into ALI calculations (Figure 5).  
 
Figure 5: Biomarkers used in the calculation of allostatic load (Read & Grundy 2012). 
 
The statistical methods and approaches used to create composite ALIs have also varied 
among past studies. The original ALI used a count base method in which the sample 
distribution for each biomarker was divided into quartiles and participants with values that 
fell within the highest quartile were given a score of ‘1’ or ‘0’ for those not in the highest 
quartile (Seeman et al. 1997). The sum of the scores for all biomarkers resulted in the 
individual participant’s ALI (0 – 10) (Seeman et al. 1997). Another statistical method used to 
measure AL is the z-score method, which is a summary measure that represents the sum of 
an individual’s  z-scores for each biomarker based on the sample’s distribution of biomarker 
values (Juster et al. 2010; von Känel et al. 2003). This method allows the weight of each 
biomarker to be considered differently depending on its deviation from the mean.  
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The utilisation of a composite measure of AL has increased over the last two decades with the 
majority of studies using ALIs in relation to health and cognitive outcomes throughout the 
lifespan (Juster et al. 2010) or for comparing the AL of a stress or diseased cohort to a healthy 
cohort (Glover et al. 2006). The MacArthur Successful Aging Study was the first study that 
utilised an ALI as a cumulative measure of biological burden. This longitudinal study used ALI 
as a predictor of disease and health deterioration in the elderly (Seeman et al. 2001). This 
study revealed that those with higher AL showed greater declines in cognitive and physical 
functioning and had higher risks of CVD and all-cause mortality (Seeman et al. 2001). The 
results of the MacArthur Study and subsequent research has provided evidence for ALIs that 
utilise a multisystem measure, to potentially predict a range of health outcomes (Juster et al. 
2010). Composite measures of allostatic load have been widely used in investigative studies, 
with the majority of research that incorporates an ALI, utilising a baseline ALI as a longitudinal 
predictive index in relation to health and cognitive outcomes throughout the lifespan of the 
cohorts (Juster et al. 2010). Although there are few studies that assess the change in AL to 
date, Juster et al. (2010) suggests that the next stage in AL research could be to assess the 
efficacy of interventions in reducing AL. 
  
1.4 Psychological interventions and stress biomarkers in breast cancer 
survivors 
The escalating number of survivors and the increased awareness of the psychological distress 
experienced by many breast cancer survivors has identified the need to investigate 
psychological interventions that may improve the wellbeing and QoL of breast cancer 
survivors. Although it has been identified that breast cancer survivors are vulnerable to 
increased stress and stress-related symptoms, the investigation of psychological 
interventions in this population is still limited (Haydon et al. 2018; Meneses et al. 2007).  
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Commonly, the effectiveness or efficacy of psychological interventions is measured by the 
analysis of participant self-assessed surveys, including validated psychological instruments or 
interviews that measure QoL, depression, anxiety and fatigue. Due to the increased 
understanding of the effects of psychological stress on physiological stress response systems, 
investigations into biomarkers of stress in psychological interventions has become a 
developing area of research (O’Leary et al. 2016), particularly in the breast cancer survivor 
population (Haydon et al. 2018) indicating that this area of research in breast cancer survivors 
is still in its infancy (O’Leary et al. 2016).  
1.4.1 Mindfulness-based psychological interventions and stress biomarkers 
Although past research has reported on the benefits of psychological interventions in 
improving QoL for breast cancer survivors, there is a limited number of studies that assess the 
effects on stress biomarkers. The majority of research literature exploring the effects of 
psychological interventions on stress biomarkers in breast cancer survivors utilises 
mindfulness-based interventions (MBIs). Mindfulness is defined as paying attention to the 
present moment, with non-judgemental acceptance of experience (Carlson 2016). The 
objective of mindfulness practices is to enhance the quality of being mindful in everyday life 
(Carlson 2016). The practice of mindfulness may improve emotion regulation, cognitive and 
behavioural flexibility and as such is thought to have beneficial effects on stress response 
systems (Epel et al. 2009). Investigations in MBIs in breast cancer survivors have assessed 
biological outcomes such as heart rate and blood pressure as well as biomarkers such as, 
cortisol, proinflammatory cytokines, and more recently telomere length and sAA. 
Mindfulness-based stress reduction (MBSR) is the most commonly studied MBI in breast 
cancer survivors as it has been shown to improve QoL and reduce symptoms of fatigue, 
depression, anxiety and fear of recurrence (Carlson et al. 2004; Johns et al. 2015; Lengacher 
et al. 2014; Matousek et al. 2011). In addition to improving psychological symptoms and QoL, 
evidence is beginning to indicate that participation in MBIs such as MBSR, may be associated 
with alterations in biomarkers of stress (Rouleau et al. 2015).  
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A MBSR intervention in breast cancer post-treatment outpatients by Carlson et al. (2004) 
found alterations in morning cortisol concentrations. The alterations varied (increased or 
decreased), depending on individual pre-intervention cortisol concentrations, suggesting that 
MBSR has effects on cortisol concentrations but the response depends on the individual 
participant’s initial concentrations (Carlson et al. 2004). Cortisol concentrations were also 
investigated by Matousek et al. (2011) in a MBSR study in breast cancer survivors. The study 
identified that breast cancer survivors had perturbed cortisol diurnal rhythm concentrations 
pre-intervention and that MBSR participation returned cortisol concentrations towards 
expected diurnal rhythm concentrations  (Matousek et al. 2011). These two studies suggested 
that participation in a MBSR intervention influences the HPA axis in breast cancer survivors, 
as evidenced by alterations in cortisol concentrations following the interventions. 
A one-year follow-up assessment of cortisol and proinflammatory cytokines after a MBSR 
intervention in breast cancer survivors identified that the improved cortisol concentrations 
resulting from the intervention were maintained after one-year and that there was also a 
continuing decrease in the concentration of TNF after the intervention (Carlson et al. 2007). 
They also identified that participation in MBSR had positive effects on blood pressure and 
heart rate (Carlson et al. 2007). This evidence indicates that participation in an MBI could 
result in long-term physiological benefits, but further longitudinal studies are required to 
support this concept. 
Evidence is beginning to emerge that stress-reducing interventions may improve telomere 
length and telomerase activity (Lengacher et al. 2014). It has been reported that the 
psychological process of mindfulness disrupts the stress response pathways thus decreasing 
the physiological stress response and therefore promoting telomere maintenance (Lengacher 
et al. 2014). There are limited studies in breast cancer survivors that assess the effects of a 
MBI on telomere length and telomerase activity. A study by Lengacher et al. (2014) utilised 
MBSR in breast cancer survivors, and identified increased telomerase activity in PBMCs, but 
no changes in telomere length over the six-week intervention. This indicates that alterations 
in telomere length may not be evident in such short periods and so should be measured at 
longer follow-up time points. It is suggested that changes in telomere length in response to a 
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psychological intervention may take at least one year (Lengacher et al. 2014). Carlson et al. 
(2015) also studied the effects of MBSR on telomere length in breast cancer survivors. This 
study identified that telomere length was maintained over a three month intervention period 
in participants compared to the control condition in which it was demonstrated that telomere 
length decreased (Carlson et al. 2015). This result suggests that MBIs such as MBSR may slow 
the attrition of telomeres in breast cancer survivors experiencing psychological stress. 
The effects of two mind-body interventions (mind-body bridging and mindfulness meditation) 
on sAA concentrations were investigated by Lipschitz et al. (2013) in a population of both 
male and female cancer survivors. Reductions in waking sAA concentrations post-intervention 
in the mind-body bridging participants were evident, suggesting positive influences of the 
intervention on SNS activity in cancer survivors (Lipschitz et al. 2013). The investigation of the 
effects of MBIs on sAA is extremely limited with the study by Lipschitz et al. (2013) being the 
only study in cancer survivors. 
Bower et al. (2015) investigated the effects of a mindfulness meditation intervention based 
on mindful awareness practices, in young breast cancer survivors. Circulating biomarkers of 
inflammation assessed included IL-6, sTNF-RII. It was found that the intervention led to 
improvements in fatigue and sleep disturbance, but IL-6 was the only biomarker that 
decreased in concentration over the course of the intervention (Bower et al. 2015). While, 
there is emerging evidence that MBIs have positive effects on biomarkers of stress more 
studies are needed to further support the current evidence. 
1.4.2 Acceptance and commitment therapy (ACT) and stress biomarkers 
Acceptance and Commitment Therapy (ACT) is a psychological intervention that incorporates 
acceptance and mindfulness-based strategies (Graham et al. 2016) and has been shown to be 
effective in a diverse range of clinical conditions (Öst 2014). ACT doesn’t aim to reduce 
physiological symptoms but rather improve psychological flexibility and therefore the ability 
to cope with symptoms (Harris 2006). The goal of ACT is to create a rich and meaningful life, 
while accepting the pain that inevitably accompanies life (Harris 2006). While ACT has not 
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been previously investigated in breast cancer survivors it has been found to have a positive 
effect on mood and QoL as a one on one intervention, in a cohort of breast cancer patients 
(Feros et al. 2013). ACT has also been found to be an effective intervention in participant 
cohorts with depression and anxiety (Feros et al. 2013), and as many breast cancer survivors 
experience both depression and anxiety it is hypothesised that a group-based ACT 
intervention may be effective in improving QoL and reducing levels of stress biomarkers in 
breast cancer survivors. 
 
1.5 Knowledge gaps  
The analysis of stress biomarkers is increasingly being used as a measure of efficacy for 
psychological interventions, indicating that the intervention may not only have effects on 
psychological health, but also on physiological health (Kryza 2011).  
The evidence from MBIs in breast cancer survivors indicates that psychological interventions 
that incorporate mindfulness may be beneficial in dealing with psychological and physical 
stressors related to cancer diagnosis, treatment and survivorship, such as fatigue, depression, 
anxiety and fear of recurrence (Carlson 2016). There is emerging evidence that MBIs in the 
breast cancer survivor population may have an effect on stress biomarkers but  it still remains 
unclear whether these biological changes translate to clinically important health benefits 
(Rouleau et al. 2015). 
The use of ACT in the cancer survivorship space is in its infancy however there is emerging 
evidence of its effectiveness in improving psychological wellbeing and quality of life when 
delivered in individual therapy sessions. The effectiveness of group-based delivery of ACT in 
improving quality of life in breast cancer survivors has not yet been reported. It is also 
unknown whether an ACT intervention can affect physiological or molecular biomarkers of 
stress in cancer survivors. 
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1.6 Project hypothesis and aims 
The overall project hypothesis was that a six-week program of ACT delivered in a group-based 
setting will lead to a reduction in physiological stress in breast cancer survivors. This reduced 
stress will be measured as alterations in the individual physiological and molecular 
biomarkers of stress, inflammation and chromosomal stability. It is also hypothesised that the 
ACT intervention will reduce participants’ cumulative AL. 
The project investigated whether ACT is beneficial in reducing physiological and molecular 
stress biomarkers by analysing pre- and post-intervention measures of: 
1. Resting heart rate, blood pressure and fasting blood glucose;  
2. Relative telomere length in PMBCs using DNA extraction and real-time polymerase 
chain reaction; 
3. Inflammatory cytokine IL-6 using enzyme-linked immunosorbent assay (ELISA); 
4. Stress hormones including salivary cortisol and salivary alpha amylase using ELISA. 
This project also aimed to develop an AL change calculation that could be used to assess the 
change in AL that incorporates biomarkers of stress from multiple systems, including 
cardiovascular, metabolic, endocrine and immune system biomarkers to determine if a six-
week program of group-based ACT is effective in reducing cumulative physiological stress in 
breast cancer survivors. 
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Group 1         Group 2        Group 3 
Chapter 2: Materials and Methods 
2.1 Study design 
The study was a randomised control crossover trial with three Groups (1, 2 and 3) and a cross 
over between the two interventions as outlined in Figure 6. Group 1 attended weekly 90-
minute group-based Acceptance and Commitment Therapy (ACT) sessions for six weeks 
followed by 90-minute group-based breast cancer education (BCE) sessions for six weeks. 
Group 2 attended 90-minute group-based BCE sessions followed by 90-minute group-based 
ACT sessions. Finally, Group 3 were waitlisted and did not attend an intervention for the first 
six weeks and then attended 90-minute group-based ACT sessions in the following six weeks. 
The study had Human Research Ethics Committee approval from both the Darling Downs 
Hospital and Health Service (HREC/17/QTDD/51) and the University of Southern Queensland 
(USQ H17REA184). The trial also had approval from the St Andrew’s Hospital Governance 
Committee to be conducted in the Hospital’s group activity rooms. The study was registered 
by the Australia and New Zealand Clinical Trials Group (Registration number 
ACTRN12617001322325), http://www.ANZCTR.org.au/ACTRN12617001322325.aspx.  
 
 
ACT
BCE
BCE
ACT
Waitlist
ACT
Measurement time points
Week 1 (T1)
Week 6 (T2)
Week 12 (T3)
6 Month Follow-up 
(T4)
Intervention 1 
Intervention 2 
 
Figure 6: Diagram of the trial design and biomarker measurement time points. 
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2.2 Participants 
Potential participants were invited by the Blush Breast Care Nurse from St Andrew’s Hospital 
to attend an initial screening interview conducted by a clinical psychologist (USQ PhD student 
May Chi). Participants provided informed consent and completed an information 
questionnaire prior to their screening interview.  Participants were informed of their eligibility 
at the completion of their screening interview. Eligible participants were female (older than 
18 years old) who had completed all primary treatments (surgery, neoadjuvant or adjuvant 
chemotherapy and radiation therapy) for early (stage 1 – 3) breast cancer at least three 
months and no longer than two years previously.  Participants were ineligible if they were 
currently undergoing treatment with a psychiatrist or mental health therapist and if they had 
a history of prior mood disorder diagnosed before their cancer diagnosis.  A total of 24 
individuals were enrolled in the trial.  
 
2.3 Randomisation   
Randomisation was conducted using Microsoft Excel, once 24 eligible participants were 
identified. Participants were randomised into one of three Groups: 1, 2 or 3, with a 1:1:1 ratio. 
The intervention commenced within two weeks of group allocation. 
 
2.4 Interventions 
2.4.1 Acceptance and commitment therapy 
The group-based ACT intervention protocol was based on the individual session protocol 
utilised in the Feros et al. (2013) study, developed by Joseph Ciarrochi and John Blackledge 
(University of Wollongong, New South Wales). The protocol was adapted from nine, 60-
minute, individual sessions to six, 90-minute group sessions. Two ACT trained psychologists 
facilitated the group sessions over six consecutive weeks.  The protocol consisted of a 
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facilitator manual and individual participant work books. The work book provided structure 
for the four modules targeting the ACT processes of increasing effective action, orientation, 
mindfulness, self-context and formal value clarification and commitment. 
2.4.2 Breast cancer education 
The breast cancer education (BCE) intervention was utilised as a control intervention, to 
control for the effect of social interaction amongst breast cancer survivors (without ACT). The 
BCE intervention consisted of six, weekly group information sessions of 90-minutes in 
duration. Guest speakers who were experts in their respective topics facilitated the BCE 
sessions. Each speaker provided information or activities to improve the self-care of breast 
cancer survivors. Topics included yoga and meditation, sexuality after treatment, exercise and 
osteoporosis, diet and nutrition, and mindfulness. Sessions were conducted at the same time 
and at the same venue (St Andrew’s Hospital) as the ACT sessions. 
 
2.5 Physiological and molecular biomarkers  
2.5.1 Demographics and clinical characteristics 
Demographic and clinical information were obtained in the initial questionnaire (Appendix A) 
at the time of study enrolment, including participant’s age, breast cancer clinical 
characteristics, treatment modalities and time since diagnosis. 
2.5.2 Physiological measures 
Physiological measures were assessed at four measurement time points during the study. The 
first measurement time point (T1) was pre-intervention 1 and was measured the morning 
before the Group 1 and 2 sessions began. The subsequent measurement time points were at 
week six (T2 - post-intervention 1/pre-intervention 2), week twelve (T3 - post-intervention 2) 
and at six months after completion of the second intervention (T4 - six month follow-up) 
(Figure 6). Group 3 participants were also required to attend all measurement time points on 
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the same days as participants from the other two Groups. Physiological measures included 
resting heart rate (bpm) and blood pressure (mmHg). Resting heart rate was measured using 
a fingertip pulse oximeter model SB100 (Rossmax Innotek Corp., Taipan, Tiawan) and blood 
pressure was measured using a Welch Allyn blood pressure cuff, stethoscope and 
sphygmomanometer (Hill-Rom, New York, USA). 
2.5.3 Molecular biomarkers 
Fasting blood specimens were collected at the same four time points as physiological 
measures (T1, T2, T3 and T4), by qualified phlebotomist, Edward Bliss. Blood was collected 
into two vacutainer tubes: one 4.5ml plasma separator tube (PST) II lithium heparin tubes and 
one 4ml ethylenediamine tetraacetic acid (EDTA) tube (Becton-Dickinson, Plymouth, United 
Kingdom). The vacutainer tubes were mixed well and then stored in a cooler until processing 
in the USQ laboratory. Blood collection tubes were centrifuged at 3,000 revolutions per 
minute (rpm) for 10 minutes to separate blood components. Plasma was removed from each 
tube and aliquoted into 2.5 mL microcentrifuge tubes, labelled with participant identification 
number, collection date, time point and stored at -80°C until molecular biomarker analysis 
could be performed on all specimens at one time. Buffy coats, containing peripheral blood 
mononuclear cells, were removed from the EDTA vacutainer tubes and stored at -80°C until 
DNA extraction could be performed. Fasting blood glucose was measured using an Accu-Chek 
Performa (Roche, Mannheim, Germany), following the collection of blood samples before 
venous clotting at the same venepuncture site to minimise participant discomfort.  
Participants were provided with Salivettes (Sarstedt, Nübnbrecht, Germany) at study 
enrolment and were instructed to collect saliva upon waking, before getting out of bed, on 
the morning of each collection time point (T1, T2, T3 and T4) for the duration of the study 
(see Appendix B). Salivettes were stored at -20°C until processing in the USQ laboratory.  
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2.5.4 DNA extraction 
Total genomic DNA was extracted from buffy coats using an Invitrogen Pure Link® Genomic 
DNA Mini Kit (Life Technologies Corp., Carlsbad, CA, USA). The manufacturer’s protocol for 
human blood specimens was followed. To each specimen of 200 µL of buffy coat, 20 µL of 
Proteinase K and 20 µL of RNAse A was added. The mixtures were briefly vortexed and then 
incubated at room temperature for two minutes.  200 µL of lysis/binding buffer was then 
added to each tube, they were briefly vortexed and incubated at 55°C for 10 minutes. 
Approximately 640 µL of specimen lysates were transferred to spin columns with collection 
tubes and centrifuged for one minute at 10,000 rpm. Collection tubes and contents were 
discarded, and new collection tubes were added to the spin columns. 500 µL of wash buffer 
1 was added to each spin column (containing the DNA specimens), followed by centrifugation 
at 10,000 rpm for one minute. Collection tubes and contents were again discarded, and new 
collection tubes were placed beneath the spin columns. 500 µL of wash buffer 2 was added 
to the spin columns, followed by centrifugation at maximum speed for three minutes. 
Collection tubes and contents were discarded, and spin columns placed in 1.5 mL 
microcentrifuge tubes. 25 µL of elution buffer was added to each spin column and each was 
incubated for one minute at room temperature and then centrifuged at maximum speed for 
one minute to remove the extracted genomic DNA from the spin column into the 
microcentrifuge tube. Extracted genomic DNA was then stored at -80°C until quantification 
and purity was assessed using a nanospectrophotometer (7122V2.4.2) (Implen, München, 
Germany).  
2.5.5 Relative telomere length 
The relative telomere length (RTL) of each genomic DNA sample was measured using a 
monochrome multiplex quantitative real-time polymerase chain reaction (MMqPCR) 
technique utilising protocols from both (Cawthon 2009) and (Hsieh et al. 2016). Genomic DNA 
from each buffy coat specimen was quantified and diluted in deionised water to 20 ng/mL. 
All specimens were assessed in triplicate reactions in one 384-well PCR plate. Each reaction 
was run using 2 µL of sample genomic DNA and 13µL of master mix. The master mix for each 
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reaction contained 8 µL of SsoAdvanced™ Universal SYBR® Green Supermix (Biorad, Hercules, 
CA, USA), 1 µl of 5M Betaine, 2 µL deionised water, 0.5 µL of each DNA oligonucleotide primer 
(Telg, Telc, Albd, Albu, see Table 1) (Integrated DNA Technologies, Republic of Singapore).   
Table 1: Oligonucleotide primer sequences  
Telg: 5’- ACA CTA AGG TTT GGG TTT GGG TTT GGG TTT GGG TTA GTG T - 3’ 
Telc: 5’- TGT TAG GTA TCC CTA TCC CTA TCC CTA TCC CTA TCC CTA ACA - 3’ 
Albd; 5’- GCC CGG CCC GCC GCG CCC GTC CCG CCG GAA AAG CAT GGT CGC CTG TT - 3’ 
Albu: 5’- CGG CGG CGG GCG GCG CGG GCT GGG CGG AAA TGC TGC ACA GAA TCC TTG - 3’ 
 
The MMqPCR was run using a C1000 Touch Thermal Cycler CFX384 real-time PCR system 
(Biorad, Hercules, CA, USA). The thermal cycling profile was programmed as follows: Stage 1 
- 15 minutes at 95°C. Stage 2 - 15 seconds at 94°C, 15 seconds at 49°C, (2 cycles). Stage 3 - 15 
seconds at 94°C, 10 seconds at 62°C, 15 seconds at 74°C (with fluorescent signal acquisition), 
10 seconds at 84°C, 15 seconds at 88°C (with fluorescent signal acquisition), (25 cycles). Stage 
4 - melt curve analysis (72°C - 95°C) signal acquisition at 0.5°C intervals with 30 second holds. 
Signals acquired from the melt curve analysis confirmed there were two melting peaks and 
therefore two different amplicons. Two cycle quantification (Cq) values were obtained for 
each reaction, Cq (T) for the telomere primer amplicon and Cq (S) for the single copy gene alb 
primer amplicon. Reaction Cq triplicates were assessed for precision and Cq values that varied 
by more than 0.5 Cq values were removed from the analysis. Both Cq averages were 
calculated for each DNA sample for the calculation of RTL via the comparative delta-delta Cq 
method:   
𝑹𝑻𝑳 = 𝟐−(∆∆𝑪𝒒) 
          = 𝟐−(𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒒 (𝑻)−𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒒 (𝑺))−(𝑹𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆 𝑪𝒒 (𝑻)−𝑹𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆 𝑪𝒒 (𝑺)) 
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This method used the same control sample as the reference for all DNA samples. The 
difference between the telomere amplicon and the single copy gene amplicon was calculated 
for each sample and the reference sample to determine the telomere length of the sample 
relative to the reference telomere length, resulting in the RTL for each specimen.  
2.5.6 Interleukin-6  
Interleukin-6 (IL-6) concentrations for each plasma specimen separated from the EDTA blood 
tubes were quantified using a sandwich enzyme-linked immunosorbent assay (ELISA) kit, 
Human IL-6 ELISA MAX™ Deluxe Set (Biolegend, San Diego, CA, USA). Individual specimens 
were assayed in duplicate on the same 96-well ELISA plate. A total of two plates were used, 
both plates were run on the same day under the same conditions. A control sample was used 
as a quality control on both plates to allow for adjustment for inter-plate variance. All 
reagents and samples were prepared as outlined in the manufacturer’s protocol. The ELISA 
was performed by initially adding 100 µL of capture antibody to all wells in both ELISA plates. 
Plates were then sealed and incubated at 4°C overnight. After 16-18 hours incubation to coat 
the wells with the primary capture antibody, the plates were then washed four times with 
wash buffer. The plates were then blocked by adding 200 µL of assay diluent A to each well, 
sealed and incubate at room temperature for one hour with shaking on a plate shaker. Plates 
were again washed four times with wash buffer. 100 µL of each specimen, standard or control 
was then added to the appropriate wells, plates were then sealed and incubated at room 
temperature for two hours with shaking on a plate shaker. Both plates were washed a further 
four times with wash buffer and 100 µL of avidin-horseradish peroxidase solution was added 
to each well. Plates were then sealed and incubated at room temperature for 30 minutes. A 
final wash was performed five times with wash buffer and 100 µL of freshly mixed TMB 
substrate solution was added to each well and incubated in the dark for thirty-minutes to 
produce a blue colour in proportion to the concentration of the IL-6 present in the specimen. 
100 µL of stop solution was then added to each well turning positive wells from blue to yellow. 
The absorbance of each well at 450 nm was then read on a Fluostar Omega 96-well ELISA 
plate reader (BMG Labtech, Offerburg, Germany). Average absorbance values were calculated 
for each individual specimen, standard and control. Control absorbancies from both ELISA 
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plates were used to adjust and correct for inter-plate variance. Standard values were used to 
create standard curves for each plate and the IL-6 concentrations of each individual specimen 
were calculated from the standard curves.  
2.5.7 Salivary cortisol  
Cortisol concentrations in saliva samples collected from the Salivettes were measured using 
a competitive ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA). All individual specimens 
were prepared by firstly centrifuging Salivettes at 3,000 rpm for five minutes and removing 
saliva specimens from the collecting tubes. Each specimen was then diluted to a 1:4 ratio in 
assay buffer as per the manufacturer’s protocol for human saliva. All specimens were assayed 
in duplicate with all specimens for the same individual participant measured on the same 96-
well plate. Two plates were used in total and both plates were assayed on the same day under 
the same conditions. 100 µL of assay buffer, standard or specimen was added to the 
appropriate wells (as determined by random allocation on a plate layout sheet). 50 µL of blue 
conjugate was then added to each well, except the total activity and blank wells. 50 µL of 
yellow antibody was added to each well, except the blank, total activity and non-specific 
binding wells. Plates were then sealed and incubated at room temperature on a plate shaker 
for two hours. After incubation, all wells were washed three times with wash solution. Wells 
were then emptied and 5 µL of blue conjugate was added to the total activity wells and 200 
µL of the pNpp substrate solution was then added to all wells. Plates were again sealed and 
incubated at room temperature without shaking for one hour. The reactions were then 
stopped by adding 50 µL of stop solution to each well. The absorbance at 405 nm of each well 
was then read immediately using a Fluostar Omega 96-well ELISA plate reader (BMG Labtech, 
Offerburg, Germany). Cortisol concentrations for each individual saliva specimen were then 
determined using the same standard curve methods as described for IL-6.  
2.5.8 Salivary alpha-amylase 
Concentrations of alpha-amylase in saliva samples were measured from the same saliva 
samples as cortisol concentrations using a liquid phase enzymatic assay kit (IBL international, 
Hamburg, Germany). All reagent, standards and specimens were prepared as per the 
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manufacture’s guidelines, with specimens being diluted in dilution buffer to a factor of 1:301. 
All specimens were assessed in duplicate, with all specimens for the same individual 
participants being analysed on the same 96-well ELISA plate. Two plates were used in total, 
both plates were assayed on the same day under the same conditions. A quality control 
specimen was assayed on both plates. 10 µL of each control, standard and specimen were 
added to appropriate wells. 200 µL of substrate solution was then added to each well and 
plates were gently shaken and incubated at room temperature for three minutes and the 
absorbance at 405 nm was promptly measured (measurement 1) using a Fluostar Omega 96-
well ELISA plate reader (BMG Labtech, Offerburg, Germany). The plates were incubated for a 
further five minutes and absorbance at 405 nm was again measured (measurement 2). 
Concentrations of sAA were then calculated by determining the change in absorbances from 
measurement 1 to measurement 2 and then using the same standard curve methods as 
described previously for IL-6. 
2.5.8 Statistical analysis 
Data analysis was performed using Statistical Package for Social Scientists (SPSS) version 25 
(IBM, Armonk, NY, USA). One-way ANOVA and parametric paired and independent t-tests 
were used for various forms of analyses and are described in more detail later in this section. 
Where the parametric tests produced significant (p < 0.05) results the analysis was repeated 
using the non-parametric equivalent test (i.e. Wilcoxon-Signed Ranks test or Mann-Whitney 
U test). The parametric t-test is a more powerful test unless the assumption of normality is 
violated. Given the small sample sizes in this study, tests of normality would be inconclusive 
and therefore the non-parametric test results were used as an alternate method of checking 
that conclusions drawn from statistically significant parametric analyses were not subject to 
inflated Type I error rates. In all cases the nonparametric test produced similar significant 
results as the parametric tests and the parametric test results are therefore reported.  
Baseline descriptive statistics were calculated for four demographic variables (mean and SD) 
and four clinical characteristic variables (percentage frequencies and n).  A one-way ANOVA 
was performed for each of the four demographic variables (age, time since diagnosis, weight 
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and BMI) to determine if there were any significant mean differences among the three groups 
of participants.  Within each biomarker variable the by-group cell counts included at least 
some cells with zero frequencies or expected counts < 5, and therefore no statistical analysis 
(such as, χ2 tests) were applied.  
Group-by-time boxplots were created to descriptively illustrate the distributions of values 
observed for each of the eight biomarkers. Pair-wise dependent samples t-tests (α = 0.05) 
among the different measurement time points were performed for each group separately. 
Due to the large number of missing values (and therefore a decrease in sample sizes from 
those used in the descriptive analyses) only T1, T2 and T3 were analysed for heart rate, 
systolic and diastolic blood pressure, blood glucose, salivary cortisol, alpha-amylase and IL-6. 
Only T1 and T4 were analysed for RTL as changes in RTL require longer than 6 or 12 weeks to 
become evident. For each biomarker variable, group-by-time bar plots showing the mean ± 2 
SEM were used to illustrate the results of the dependent samples t-tests. Due to the lack of a 
washout period between intervention 1 and intervention 2 it could not be assumed that the 
effects of intervention 1 had not subsequently influenced the data recorded at T3.  
To investigate any effects of the ACT intervention on a larger sample size than available within 
each group, the measurement time points corresponding to pre- and post-ACT intervention 
for all participants were combined. T1 and T2 were the respective pre- and post-ACT 
measurements for Group 1, and T2 and T3 were the respective pre- and post-ACT 
measurements for Group 2 and Group 3. The pre- and post-ACT data for each variable was 
then analysed using pair-wise dependent t-tests with a significance level of α = 0.05. Pearson 
correlation coefficient (r) between pre- and post-ACT measures for each of the biomarkers 
was calculated, as well as the effect size using Cohen’s D statistic for paired samples: 𝐷 =
𝑡
√𝑛
  
(Lakens 2013).  
An estimate of change in cumulative allostatic load (AL) was calculated for each participant 
using the change between pre- and post-ACT measurements averaged over six biomarkers of 
allostasis: heart rate, systolic and diastolic blood pressure, fasting blood glucose, IL-6 and 
cortisol. Only those participants with pre and post measures for at least five of these six 
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variables were included in the AL calculations. The change in each biomarker from pre- to 
post-ACT intervention measurements was first calculated for each participant and then these 
difference values were normalised by calculating z-scores. The mean and standard deviation 
of the six normalised difference variables were then calculated to give an estimate of the 
change in AL for each participant associated with the ACT intervention. Z-scores were used 
instead of raw differences to ensure that each variable contributed equally to the calculation 
of the mean change in AL. The mean change in allostatic load ± 1 SD was plotted for each 
participant (n = 15) for visual and descriptive comparison. A one-sample t-test was used to 
test if the mean change in allostatic load among the 15 participants was significantly different 
to zero (α = 0.05). In addition, a one-way ANOVA was used to determine if the mean change 
in allostatic load was different among the three Groups of participants and subsequent post-
hoc Least Significant Difference (LSD) pairwise tests were used to identify individual 
significant group difference (α = 0.05). 
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Chapter 3: Results 
3.1 Participants 
Twenty-four participants were initially enrolled in the trial; however, two participants 
withdrew before measurement time point 1 (T1). A further two participants withdrew within 
the first six weeks of the trial due to ill health for one participant and an unexpected time 
commitment for the second participant. Data for these two participants are not included in 
final data analysis. Not all participants provided full data on each measure at each time point 
for a range of reasons including not attending the collection time appointment, forgetting to 
collect their saliva specimen at the correct time or an inability to obtain blood samples. The 
latter is a common side effect of chemotherapy treatment as veins collapse or become 
scarred due to repeated venepuncture for drug delivery and blood tests (Piredda et al. 2017).  
3.2 Demographics and clinical characteristics 
Baseline demographic data and clinical characteristics are reported in Table 2. The number of 
participants (n) at baseline for Groups 1, 2 and 3 were 7, 6 and 7 respectively. Participants 
were a mean age of 59.3 (SD = 4.5), 50.5 (SD = 3.8) and 58.3 (SD = 10.4) years old for Groups 
1, 2 and 3 respectively. Average time since breast cancer diagnosis ranged from 28.29 (SD = 
15.9) months for Group 1 to 35.86 (SD = 21.2) months for Group 3. No significant differences 
(p > 0.05) were found between Groups for the four demographic variables: Age, Time since 
diagnosis, Weight and BMI. Four participants within each group had oestrogen positive breast 
cancer, and one participant from Group 3 reported progesterone positive breast cancer 
(Table 2). One participant in each group indicated hormone receptor classification as 
unknown, and the remaining participants (n = 2, 1 and 1, for Groups 1, 2 and 3 respectively) 
reported hormone receptor negative breast cancer. Four participants from Group 1 reported 
human epidermal growth-factor receptor 2 (HER-2) positive cancer, with another two 
participants reporting HER-2 negative and one participant reporting unknown classification. 
No participants from Groups 2 or 3 reported HER-2 positive. However, unknown HER-2 
classification was reported at n = 2 and n = 3, for Groups 2 and 3 respectively. HER-2 was 
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reported as negative for n = 4 participants, for both Group 2 and 3. Over half of all participants 
reported receiving both radiotherapy and chemotherapy treatments.  Between 28 % (Group 
1) and 67 % (Group 2) of participants were receiving continuing hormone therapy. Group 3 
participants had the highest mean BMI, 31.43 (SD = 9.3), this was not significantly different to 
Group 1 or Group 2.  
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Table 2: Baseline descriptive statistics for demographic and clinical characteristics of 
participants within each group. Relevant mean and standard deviation (SD) or percentage 
frequencies (%) and number (n) of participants are given. No mean significant differences 
(p > 0.05) were found among groups for any of the four demographic variables. 
  
 
Group 1 
(n = 7) 
Group 2 
(n = 6) 
Group 3 
(n = 7) 
Age (years), mean (SD) 57.86 (7.48) 56.33 (9.65) 54.71 (6.63) 
Time since diagnosis (months), mean (SD) 28.29 (15.91) 31.00 (17.85) 35.86 (21.24) 
Weight (kg), mean (SD) 76.59 (13.72) 82.75 (17.34) 83.79(21.56) 
BMI, mean (SD) 28.25 (4.27) 27.67 (5.62) 31.43 (9.34) 
    
Breast affected, % (n) 
   
     Both 14.29 (1) 16.70 (1) 28.57 (2) 
     Left 42.86 (3) 33.33 (2) 42.86 (3) 
     Right 42.86 (3) 50.00 (3) 28.57 (2) 
Hormone receptor type, % (n) 
   
     Oestrogen positive 57.14 (4) 66.66 (4) 57.14 (4) 
     Progesterone positive 0.00 (0) 0.00 (0) 14.29 (1) 
     Receptor negative 28.57 (2) 16.70 (1) 14.29 (1) 
     Unknown 14.29 (1) 16.70 (1) 14.29 (1) 
HER2 receptor positive, % (n) 
   
     Yes 57.14 (4) 0.00 (0) 0.00 (0) 
     No 28.57 (2) 66.66 (4) 57.14 (4) 
     Unknown 14.29 (1) 33.33 (2) 42.86 (3) 
Treatment modality, % (n) 
   
     Radiotherapy 57.14 (4) 87.50 (6) 87.71 (6) 
     Chemotherapy 87.71 (6) 75.00 (6) 71.43 (5) 
     Hormone therapy – past 28.57 (2) 0.00(0) 42.82 (3) 
                                       - current 28.57 (2) 66.66 (4) 42.82 (3) 
     Ovarian treatments 14.29 (1) 25.00 (2) 0.00 (0) 
     Other 14.29 (1) 0.00 (0) 0.00 (0) 
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3.3 Physiological and molecular biomarkers 
3.3.1 Heart rate 
The heart rates for participants in Group 1 had similar distribution ranges for measurement 
time points T1, T2 and T3 (T1: 61 – 79 bpm, T2: 62 – 79 bpm, T3: 64 – 79 bpm) with a larger 
range at the six-month follow-up measurement time point, T4 (62 – 87 bpm) (Figure 6). Group 
2 had larger ranges of distribution of heart rates for measurement time points T1, T2 and T4 
(T1: 55 – 90 bpm, T2: 55 – 82 bpm, T4: 65 - 107 bpm). Group 3’s range in heart rates across 
measurement time points was largest at T3 (56 – 82 bpm). Group 3 had an outlier at three 
measurement time points (T1: 85 bpm, T2: 86 bpm, T4: 88 bpm), and this was the same 
participant in each case. The outliers were within the heart rate ranges of other two groups 
(Figure 6).  
 
Figure 6: Heart rate (bpm) for all four measurement time points for each of the three 
groups. Samples sizes for measurement time points (T1, T2, T3, T4) were: Group 1 (n = 7, 7, 
6, 7); Group 2 (n = 5, 6, 6, 5); Group 3 (n = 6, 5, 5, 6). 
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Mean heart rate did not vary significantly across time points for any group (p ˃ 0.05) (Figure 
7). Group 1 (n = 6) had a relatively consistent mean heart rate around 70.0 bpm at each 
measurement time point, with a small range of SEMs (2.02 bpm at T3 to 3.02 bpm at T2). 
There was only limited variation in the mean heart rates for Group 2 (n = 5, 69.8 ± 4.59 bpm 
at T2 to 73.4 ± 5.9 bpm at T1). Group 3 (n = 3) also had similar mean heart rates across 
measurement time points but with larger SEMs ranging from 7.5 bpm at T4 to 8.4 bpm at T3. 
 
 
Figure 7: Mean heart rate (bpm) (± 2 SEM) for each Group at T1, T2 and T3. Only participants 
with measurements at all three time points were included in these samples for analysis: 
Group 1 (n = 6), Group 2 (n = 5), Group 3 (n = 3).  
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3.3.2 Systolic Blood Pressure 
Measures of systolic blood pressure showed a relatively wide range across all measurement 
time points for each group (Figure 8), with the largest range in Group 2 at T2 (92 – 138 mmHg) 
and the smallest range also in Group 2 at T1 (121 – 140 mmHg). In the distribution of systolic 
blood pressure, the range for Group 1 was similar for T1, T2 and T3 but suggested a decreasing 
trend over these three measurement time points (T1: 119 – 143 mmHg, T3: 100 – 128 mmHg). 
Group 2’s systolic blood pressure had a relatively small range at T1 (121 – 140 mmHg) and 
larger ranges at the later three measurement time points. The Group 3 distributions of systolic 
blood pressure also suggested a decreasing trend from T1 to T4. The maximum systolic blood 
pressure for all three groups was at T1 (143 mmHg, 140 mmHg and 143 mmHg for Groups 1, 
2 and 3 respectively) (Figure 8). 
 
Figure 8: Systolic blood pressure (mmHg) for all four measurement time points for each of 
the Groups. Samples sizes for the four measurement time points (T1, T2, T3, T4) were: 
Group 1 (n = 7, 7, 6, 7), Group 2 (n = 4, 5, 5, 4), Group 3 (n = 6, 5, 5, 6). 
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Pair-wise analysis of mean systolic blood pressure among T1, T2 and T3 (Figure 9) for each 
group, indicated that the mean systolic blood pressure for Group 1 decreased significantly (p 
= 0.010, n = 6), from T1 to T3 (130 ± 3.8 mmHg to 115 ± 4.0 mmHg). The mean systolic blood 
pressure for Group 2 (n = 4) or Group 3 (n = 3) did not demonstrate any significant differences 
(p > 0.05) among any of the three measurement time points (Figure 9).   
 
Figure 9: Mean systolic blood pressure (mmHg) (± 2 SEM) for each Group at T1, T2 and T3. 
Only participants with measurements at all three time points were included in these 
samples for analysis: Group 1 (n = 6), Group 2 (n = 4), Group 3 (n = 3). Means within a group 
with significant differences are indicated with notations, different notations represent 
significant differences, p ˂ 0.05. No notation indicates no significant differences between 
the measurement time points for the group.   
 
 
 
 
a ab 
b 
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3.3.3 Diastolic blood pressure 
Diastolic blood pressure (Figure 10) had distributions with varying ranges between Groups at 
T1. Group 1’s range for diastolic blood pressure increased from T1 to T2 and then decreased 
again at T3 (68 mmHg to 78 mmHg, n = 6). The distribution at T4 for Group 1 (n = 7) was 
strongly influenced by two outliers, one higher and the other lower (75mmHg and 88mmHg). 
These outliers fell within the ranges of diastolic blood pressure at other measurement 
timepoints for Group 1. The range of diastolic blood pressure for both Group 2 and Group 3 
were similar at all four measurement time points, however both also indicated a decrease in 
both maximum and minimums from T1 to T2. The maximum diastolic blood pressure for 
Group 2 decreased from 96 mmHg at T1 to 88 mmHg at T2 and stayed at similar values at T3 
and T4 (Figure 10).  
 
Figure 10: Diastolic blood pressure (mmHg) for all four measurement time points for each 
of the three groups. Sample sizes for (T1, T2, T3, T4) were: Group 1 (n = 7, 7, 6, 7), Group 2 
(n = 4, 5, 5, 4), Group 3 (n = 6, 5, 5, 6). 
 
41 | P a g e  
 
Pair-wise analysis of mean diastolic blood pressure among times (T1, T2 and T3) for each 
group separately (Figure 11), identified that the mean diastolic blood pressure for Group 1 (n 
= 6) decreased significantly (p = 0.006) from 84.8 ± 2.4mmHg at T1 to 73.0 ± 1.7 mmHg at T3. 
The mean diastolic blood pressure for Group 2 (n = 4) and Group 3 (n = 3) were highest at T1 
(Group 2: 88.5 ± 4.5 mmHg, Group 3: 92.0 ± 2.0 mmHg), and appeared to decrease across 
measurement time points, however, there were no significant differences (p > 0.05) within 
each group.  
 
Figure 11: Mean diastolic blood pressure (mmHg) (± 2 SEM) for each group at T1, T2 and T3. 
Only participants with measurements at all three time points were included in these 
samples for analysis: Group 1 (n = 6), Group 2 (n = 4), Group 3 (n = 3). Means within a group 
with significant differences are indicated with notations, different notations represent 
significant differences, p ˂ 0.05. No notation indicates no significant differences between 
the measurement time points for the group. 
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3.3.4 Blood Glucose 
Blood glucose had a wide range for Group 1 across all measurement time points, increasing 
from T1 to T2 (Figure 12). The minimum blood glucose for Group 1 was between 4.1 mmol/L 
at T1 and 4.8 mmol/L at T3 and T4. The highest maximum blood glucose for Group 1 was at 
T2 (6.6 mmol/L). Group 2’s blood glucose had smaller distribution ranges, with the lowest 
minimum at T1 (4.3 mmol/L) and the highest maximum of 6.3 mmol/L at T3 (excluding and 
outlier of 7.3 mmol/L at T2). The ranges of blood glucose for Group 3 varied across 
measurement time points, with one outlier at T1 recording one of the lowest blood glucose 
values in the study (4.3 mmol/L). The ranges for all three time points were consistently smaller 
for Group 2 and Group 3 than the ranges for Group 1.  
 
Figure 12: Fasting blood glucose (mmol/L) for all four measurement time points for each of 
the three groups. Samples sizes for (T1, T2, T3 and T4) were: Group 1 (n = 7, 7, 6, 7), Group 
2 (n = 4, 5, 5, 4), Group 3 (n = 6, 5, 5, 6).  
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Analysis of mean fasting blood glucose for measurement time points T1, T2 and T3 by pair-
wise dependent samples t-tests, identified significant increases in mean blood glucose within 
Group 1 and Group 2 (Figure 13). Blood glucose in Group 1 (n = 6) significantly increased from 
4.98 ± 0.27 mmol/L at T1 to 5.55 ± 0.30 mmol/L at T2 (p = 0.023).  At T3 the mean of 5.62 ± 
0.22 mmol/L was significantly higher than T1 (p = 0.034) but not significantly different to T2 
(p > 0.05).  Group 2 (n = 4) significantly increased from 4.93 ± 0.21 mmol/L at T1 to 5.70 ± 0.23 
mmol/L at T3 (p = 0.018). There was no significant difference in mean blood glucose for Group 
3 (n = 3) across all three measurement time points, with the means ranging from 5.10 ± 0.10 
mmol/L at T1 to 5.30 ± 0.17 mmol/L at T2. 
 
Figure 13: Mean fasting blood glucose (mmol/L) (± 2 SEM) for each group at T1, T2 and T3. 
Only participants with measurements at all three time points were included in these 
samples for analysis: Group 1 (n = 6), Group 2 (n = 4), Group 3 (n = 3). Means within a group 
with significant differences are indicated with notations, different notations represent 
significant differences, p ˂ 0.05. No notation indicates no significant differences between 
the measurement time points for the group. 
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3.3.5 Relative telomere length 
Relative telomere length (RTL) had varying distribution ranges across measurement time 
points in each Group (Figure 14). Group 1’s range of distribution decreased from T1 to T3 with 
a similar trend for Group 2. Group 1 and Group 2 had wide ranges of distribution of RTL at T4 
(Group 1: 0.54 to 2.76, Group 2: 0.57 to 3.36). The range of distribution for Group 3 at T4 was 
strongly influenced by two outliers, one lower (0.27) and the other higher (2.82) than other 
measures. 
 
 
Figure 14: Relative telomere length for all four measurement time points for each of the 
three groups. Samples sizes for measurement time points (T1, T2, T3, T4) were: Group 1 (n 
= 6, 6, 5, 5), Group 2 (n = 4, 5, 5, 5), Group 3 (n = 6, 5, 5, 5). 
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Mean RTL appeared to increase slightly from T1 to T4 for each group, but these changes were 
not statistically significant (p > 0.05) (Figure 15). Group 1 (n = 5) increased from 1.69 ± 0.25 to 
1.83 ± 0.41. Group 2 (n = 4) increased from 1.59 ± 0.23 to 1.72 ± 0.44, and Group 3 (n = 5) 
increased from 1.75 ± 0.28 to 2.00 ± 0.45.  
 
Figure 15: Mean relative telomere length (± 2 SEM) for each group at T1 and T4. Only 
participants with measurements at both time points were included in these samples for 
analysis: Group 1 (n = 5), Group 2 (n = 4), Group 3 (n = 5). 
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3.3.6 Interleukin-6  
Interleukin-6 (IL-6) had varying ranges across measurement time points for each group (Figure 
16). Distributions of IL-6 appeared to increase in range from T1 to T2 for all groups, with the 
highest concentration of IL-6 for each group across all four measurement time points 
occurring at T2 (Group 1: 8.48 pg/mL, Group 2: 7.31 pg/mL, Group 3: 12.60 pg/mL). Group 3 
had outliers (above and below the distributions) that strongly influenced the distribution of 
IL-6 at T3 and T4, however these outliers fell within the ranges observed for Group 1 and 
Group 2. 
 
Figure 16: Interleukin-6 (pg/mL) for all four measurement time points for each of the three 
groups. Samples sizes for measurement time points (T1, T2, T3, T4) were: Group 1 (n = 6, 6, 
5, 5), Group 2 (n = 4, 5, 5, 5), Group 3 (n = 6, 5, 5, 5). 
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Mean IL-6 appeared to increase from T1 to T2 for all groups (Figure 17), but there were no 
significant differences across measurement time points within each group (p > 0.05). Group 
1’s (n = 5) mean IL-6 increased from 3.54 ± 0.58 pg/mL at T1 to 4.48 ± 1.42 at T2 and stayed 
at a similar mean concentration for T3. There was little variation in mean IL-6 concentrations 
across measurement time points for Group 2 (n = 4). Group 3’s (n = 3) mean IL-6 increased 
from 5.34 ± 0.92 at T1 to 9.60 ± 1.55 at T2 and then decreased to a mean concentration at T3, 
similar to the Group’s T1 mean Il-6. Group 3 had the highest mean IL-6 concentrations 
compared to the other groups at all measurement time points. There appeared to be changes 
in the mean IL-6 for Group 3, but these were not significant due to large variance and small 
sample size (n = 3). 
 
Figure 17: Mean interleukin-6 (pg/mL) (± 2 SEM) for each group at T1, T2 and T3. Only 
participants with measurements at all three time points were included in these samples for 
analysis: Group 1 (n = 5), Group 2 (n = 4), Group 3 (n = 3). 
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3.3.7 Cortisol 
Salivary cortisol concentration distribution ranges varied among measurement time points 
for each group (Figure 18). Group 1 had wider ranges of cortisol distribution at T1 and T2 
compared to T3 and T4 but higher outliers at both T3 and T4 (T3: 13.85 ng/mL, T4: 27.35 
ng/mL). Group 2 had similar ranges of cortisol concentrations at T1, T2 and T3 and had a 
narrower distribution range T4 (4.93 ng/mL to 7.32 ng/mL). Group 3 had relatively narrow 
distributions ranges of cortisol concentration at both T1 and T2. Group 3 also had an outlier 
at T1 and T4 (T1: 14.95 ng/mL, T4: 21.65 ng/mL). 
 
Figure 18: Cortisol (ng/mL) for all four measurement time points for each of the three 
groups. Samples sizes for measurement time points (T1, T2, T3 and T4) were: Group 1 (n = 
5, 6, 5, 5), Group 2 (n = 4, 4, 4, 3), Group 3 (n = 5, 5, 4, 6). 
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Mean cortisol concentrations across measurement time points (T1, T2 and T3) for Group 1 
and Group 2 separately had no significant differences among time points (p ˃ 0.05) (Figure 
19). The mean concentration of cortisol for Group 1 (n = 4) deceased slightly from T1 to T2 
(6.98 ± 1.73 ng/mL to 5.81 ± 1.32 ng/mL) and then increased to 7.83 ± 2.09 ng/mL at T3. Group 
2’s (n = 4) mean cortisol concentration had similar values across all three measurement time 
points. Group 3’s mean cortisol concentrations indicated a significant increase (p = 0.038, n = 
3) from T1 to T2 (5.85 ± 0.44 ng/mL to 7.42 ± 0.75 ng/mL). The mean cortisol concentration 
for Group 3 appeared to decrease at T3 (6.28 ± 2.11 ng/mL) but this was not significant 
compared to T2 (p > 0.05). 
 
Figure 19: Mean cortisol concentration (ng/mL) (± 2 SEM) for each group at T1, T2 and T3. 
Only participants with measurements at all three time points were included in these 
samples for analysis: Group 1 (n = 4), Group 2 (n = 4), Group 3 (n = 3). Means within a group 
with significant differences are indicated with notations, different notations represent 
significant differences, p ˂ 0.05. No notation indicates no significant differences between 
the measurement time points for the group. 
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3.3.8 Salivary alpha-amylase 
Concentrations of salivary alpha-amylase (sAA) had wide distributions across all 
measurement time points for each group (Figure 20). The was an outlier (same individual 
participant) at all measurement time points in Group 1, with all but the T1 outlier (490.45 
U/mL) falling within the ranges for sAA concentrations of Group 2 and Group 3. Group 2’s and 
Group 3’s ranges of sAA concentrations appeared to increase from T1 to T2. Group 2’s range 
narrowed from T2 to T4, with the smallest range at T4 (23.94 U/mL to 206.05 U/mL). Group 
3’s range increased across all measurement time points with T4 having the widest range (7.18 
U/mL to 377.76 U/mL). 
 
Figure 20: Salivary alpha-amylase (U/mL) for all four measurement time points for each 
group. Samples sizes for measurement time points (T1, T2, T3 and T4) were: Group 1 (n = 6, 
6, 5, 5), Group 2 (n = 5, 5, 5, 4), Group 3 (n = 6, 5, 4, 6). 
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Mean sAA concentrations did not vary significantly (p > 0.05) between measurement time 
points T1, T2 and T3 for each group (Figure 21). The mean concentration of sAA at T1 for 
Group 1 appeared to be higher compared to the other groups, however this mean was also 
associated with a relatively large SEM. The mean sAA concentration of Group 1 (n = 5) 
appeared to decrease from T1 to T2 (224.64 ± 68.60 U/mL to 153.15 ± 35.15 U/mL), whereas 
the mean sAA concentration for Group 2 (n = 5) appeared to increase from T1 to T2 (82.03 ± 
38.53 U/mL to 179.96 ± 83.98 U/mL). Group 3’s (n = 4) mean sAA concentration increased 
from 86.94 ± 45.86 U/mL at T1 to 161.98 ± 80.08 U/mL. There were large variances in sAA for 
each group at all measurement time points as indicated by the large SEMs (Figure 21). 
 
Figure 21: Mean salivary alpha-amylase (U/mL) (± 2 SEM) for each group at T1, T2 and T3. 
Only participants with measurement at all three time points were included in these samples 
for analysis: Group 1 (n = 5), Group 2 (n = 5), Group 3 (n = 4). 
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3.3.9 Physiological and molecular biomarkers for pre- and post-ACT intervention 
There were no significant differences between mean values for pre- and post-ACT 
intervention samples (regardless of group) for any of the eight measured biomarkers (p > 
0.05) (Table 3). The effect size (D) of ACT on heart rate was negative and small, indicating a 
slightly higher but not significantly different post-ACT intervention measurement (D = -0.04). 
Pearson correlation analysis identified a significant positive correlation (r = 0.67, p = 0.003) 
between mean heart rates from the pre- and post-ACT intervention samples (n = 17), 
indicating a strong positive linear relationship between both heart rate measurements. There 
was a decrease in mean systolic blood pressure from pre- to post-ACT intervention measures, 
with a positive and moderate effect (D = 0.33). The correlation between the two measures 
was significant (r = 0.76, p = 0.001), indicating a moderate-strong positive linear relationship 
(Table 3). Similarly, there were moderate-strong, positive linear relationships between pre- 
and post-ACT diastolic blood pressure (r = 0.63, p = 0.009), RTL (r = 0.72, p = 0.002), cortisol (r 
= 0.81, p = 0.001) and sAA (r = 0.63, p = 0.013). The correlation coefficients for blood glucose 
(r = -0.402) and IL-6 (r = 0.512) were not significant (p > 0.05) (Table 3).  
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Table 3: Physiological and molecular biomarkers pre- and post-ACT intervention for all 
groups combined. Only participants with measurements at both time points were included 
in samples for analysis for each individual biomarker. Significant correlations between pre- 
and post-ACT measurements for an individual biomarker are identified in bold. 
  
  Time Point 
Pair-wise 
Significance 
Effect Size 
Pearson 
Correlation 
Correlation 
Significance 
    Pre-ACT Post-ACT P D r  P 
Heart    
Rate  
(bpm) 
N 17 17  
  
  
Mean 
(SD) 
70.88 
(8.67) 
71.18 
(7.67) 
0.859 -0.04 0.670 0.003 
Systolic 
Blood 
Pressure 
(mmHg) 
N 16 16  
  
  
Mean 
(SD) 
125.50 
(13.05) 
122.75 
(10.88) 
0.213 0.33 0.765 0.001 
Diastolic 
Blood 
Pressure 
(mmHg) 
N 16 16  
  
  
Mean 
(SD) 
81.13 
(8.19) 
79.50 
(9.48) 
0.410 0.21 0.631 0.009 
Blood 
Glucose 
(mmol/L) 
N 17 17  
  
  
Mean 
(SD) 
5.32 
(0.70) 
5.31 
(0.99) 
0.973 0.08 -0.402 0.110 
Relative 
Telomere 
Length 
N 15 15  
  
  
Mean 
(SD) 
1.64 
(0.44) 
1.61 
(0.35) 
0.701 0.10 0.728 0.002 
Interleukin-6 
(pg/mL)  
N 15 15  
  
  
Mean 
(SD) 
4.23 
(3.55) 
3.74 
(2.29) 
0.555 0.16 0.512 0.050 
Cortisol 
(ng/mL) 
N 13 13  
  
  
Mean 
(SD) 
7.47 
(0.93) 
7.14 
(0.92) 
0.580 0.22 0.805 0.001 
Salivary  
Alpha-
Amylase 
(U/mL) 
N 15 15  
  
  
Mean 
(SD) 
177.41 
(146.96) 
161.84 
(127.00) 
0.623 0.13 0.625 0.013 
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3.4 Allostatic load index 
The mean change in allostatic load for the 15 trial participants with a complete dataset (Figure 
22) showed each participant’s average change across the six biomarkers included in the 
allostatic load calculation (see Methods section 2.6.8). Group 3 participants all had a mean 
positive change in allostatic load, indicating that their normalised (z-score) post-ACT values 
were, on average, lower than their normalised pre-ACT values. However, for each of these 
participants the standard deviations representing the variation across the six biomarkers, 
indicated that, for at least some of the biomarkers, an increase in values from pre- to post-
ACT time points occurred (that is, a negative change in allostatic load). Participant 22 from 
Group 3 had the highest mean change allostatic load (0.55, SD = 0.96) indicating that they 
recorded the greatest average reduction in biomarker values after the ACT intervention.  
Eight of the participants (from Group 1 and Group 2) had a negative mean change in allostatic 
load indicating that post-ACT biomarker values were, on average, higher than pre-ACT values 
for these participants. The largest negative mean change in allostatic load was calculated for 
participant 19 (-0.76, SD = 1.08).  
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Figure 22: Change in allostatic load for individual participants representing the average 
change in values for pre- and post-ACT intervention biomarker measures (positive values 
indicate a positive effect i.e. an average decrease in AL. Mean ± SD of the standardised (z-
score) change in six biological variables is given for each individual. Group 1: (n = 7), Group 
2: (n = 4), Group 3: (n = 4). 
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The one-sample t-test analysis indicated that the mean change in allostatic load (n = 15) was 
not significantly different to zero (p > 0.05). However, the one-way ANOVA analysis did 
indicate a difference between at least two of the Group means (p = 0.009) and subsequent 
post-hoc pair-wise tests showed that the mean (± SEM) change in allostatic load for Group 3 
(0.35 ± 0.08, n = 4) was significantly higher (decrease in AL) than for Group 1’s (0.13 ± 0.09, n 
= 7, p = 0.01) or Group 2’s (0.29 ± 0.17, n = 4, p = 0.004)  (Figure 23).  
 
Figure 23: Mean (± 2 SEM) change in allostatic load pre- to post-ACT intervention for each 
group. Only participants with measurements for both time points for at least five of the six 
biomarkers were included in samples for analysis: Group 1 (n = 7), Group 2 (n = 4), Group 3 
(n = 4). Significant difference between groups are indicated by notations, different 
notations indicate significant differences. 
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Chapter 4: Discussion 
This pilot study investigated the effects of a six-week group-based Acceptance and 
Commitment Therapy (ACT) intervention on physiological and molecular biomarkers of stress 
in breast cancer survivors using a randomised, controlled clinical trial protocol. Physiological 
measures included resting heart rate and blood pressure and molecular biomarkers assessed 
included fasting blood glucose levels, relative telomere length (RTL) in peripheral blood 
leukocytes, plasma interleukin 6 (IL-6), salivary cortisol, and salivary alpha-amylase. The 
changes in six of these biomarkers were then used to calculate the cumulative change in 
allostatic load (AL) for participants following the ACT intervention. The primary hypothesis of 
the study was that individual biomarkers of stress would be reduced in participants following 
the ACT intervention and this was not supported by the study’s findings. The secondary 
hypothesis was that cumulative AL would reduce following the ACT intervention. The findings 
indicated that allostatic load was significantly reduced in Group 3 participants who attended 
the ACT therapy following a six-week wait but was increased in Groups 1 and 2 participants. 
The aggressive and prolonged therapies that have led to the increased survival rates from 
breast cancer can also cause adverse side effects, including impairment of cardiovascular 
functions such as elevated heart rate (Caro-Moran et al. 2016) and long term elevated heart 
rate is associated with cardiovascular disease and all-cause mortality (Anker et al. 2016). The 
study by Caro-Moran et al. (2016) investigating the resting heart rate of breast cancer 
survivors (n = 22) compared to healthy age-matched controls (50 ± 7.68 years) found that the 
breast cancer survivors had significantly higher resting heart rates (79.29 ± 11.19 bpm) 
compared to healthy controls (68.27 ± 7.6 bpm). Several other studies have reported that 
higher resting heart rate is associated with poorer prognosis in breast cancer survivors (Lee 
et al. 2016; Lee et al. 2018). Resting heart rate of the participants in this study did not change 
in response to the ACT intervention. This may be because the mean resting heart rate before 
the intervention (70.88 ± 8.67 bpm) was in the clinically healthy range and therefore not likely 
to improve. While the mean age of participants in the Caro-Moran et al. (2016) study was on 
average eight years lower than the participants in the current study, participants in this study 
had resting heart rates comparable to the healthy controls and not the breast cancer 
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survivors. This suggests that the population of breast cancer survivors in the current study 
have, on average, healthy resting heart rates.  
Elevated blood pressure (hypertension) is defined as systolic greater than 140 mmHg and/or 
diastolic lower than 90 mmHg, and is a reversible risk factor for cardiovascular disease, heart 
failure and stroke (Carlson et al. 2007; Weber et al. 2014). Breast cancer patients who have 
undergone chemotherapy and radiotherapy are at a greater risk of having damaged heart 
muscle making them more susceptible to future cardiovascular disease (Carlson et al. 2007). 
Thus, it is important for breast cancer survivors to maintain optimal blood pressure in an 
effort to reduce the risk of cardiovascular disease. There is substantial evidence in the 
literature that stress-reducing interventions can lead to decreases in blood pressure (Cohen 
et al. 2015). While a select few participants in this study had hypertension at varying 
measurement time points the average systolic and diastolic blood pressures for all 
participants pre-ACT intervention were not elevated but rather in the normal range. There 
was a small decrease in both systolic and diastolic blood pressure post-ACT intervention with 
the mean blood pressures trending towards optimal ranges of less than 120 mmHg systolic 
and  80 mmHg diastolic (Weber et al. 2014). Participants in Group 1 of the study did show a 
decrease in both systolic and diastolic blood pressure from the initial measure to post-
intervention 2 (following 12 weeks of intervention), however it is unclear if this decrease is 
due to the combination of the two interventions or if the effects of ACT are not evident until 
after a longer time period such as 12 weeks. A study by Carlson et al. (2007) utilising 
mindfulness-based stress reduction (MBSR) reported a decrease in blood pressure following 
an eight-week intervention protocol, suggesting that a longer protocol or time between 
measurements in blood pressure may be needed before effects are evident.  
Several studies have demonstrated that elevated levels of fasting blood glucose are 
associated with a poorer prognosis after breast cancer (Contiero et al. 2013; Muti et al. 2002; 
Sieri et al. 2012). Elevated fasting blood glucose is an indicator of diabetes and research has 
revealed a link between breast cancer and the development of diabetes with the risk of 
diabetes increasing two years after diagnosis (Lipscombe et al. 2013). This increase in risk is 
particularly high in patients who have had adjuvant treatment including chemotherapy, 
59 | P a g e  
 
radiation and hormonal therapy (Juanjuan et al. 2015; Lipscombe et al. 2013). This study 
identified significant increases in the fasting blood glucose concentrations for Group 1 
following the ACT intervention and in Group 2 after completion of both interventions. These 
increases in fasting blood glucose may be associated with participants’ breast cancer 
treatment (chemotherapy, radiation and hormonal therapy) as all of the participants had at 
least one form of adjuvant treatment.  
Previous research has explored the effects of psychotherapy interventions on reducing fasting 
blood glucose, most commonly in relation to obese and overweight individuals and those with 
diabetes (Raja-Khan et al. 2017). Raja-Khan et al (2017) observed a significant decrease in 
blood glucose after eight weeks of a MBSR program however, this decrease was even greater 
after 16 weeks of the program. When all participant data were combined for pre- and post-
ACT intervention in the current study, there were no significant changes in fasting blood 
glucose over the six-week ACT intervention suggesting ACT had no effect on fasting blood 
glucose over this time period. It may be that a longer ACT intervention such as a 16 week 
program is required to illicit a positive effect. 
Relative telomere length (RTL) is a measure of chromosomal stability with reduced telomere 
length in peripheral blood mononuclear cells (PMBCs) associated with accelerated cellular 
ageing (Epel 2009). Although RTL decreases with ageing, previous intervention studies have 
demonstrated that psychotherapies such as MBSR can lead to an increase in RTL or at least a 
decrease in the rate of telomere attrition (Daubenmier et al. 2012; Lengacher et al. 2014). In 
this study, RTL did not significantly change from pre- to post-ACT intervention for all 
participants combined. This result was expected as measurable changes in telomere length 
would not be evident over short periods of time such as the study’s six-week ACT intervention 
(Svenson et al. 2011). It has been suggested that stable alterations to telomere length are 
only evident after one year (Lengacher et al. 2014). At the six-month follow up, the mean RTL 
of all three groups increased from the initial measurement but there were no statistically 
significant differences suggesting that changes are perhaps occurring but may not be 
significantly different at six months. Telomere length is expected to decrease with age (Epel 
2009) however an increase may be a consequence of other factors such as recovery after 
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cancer treatments. The current literature on the effects of cancer therapies on telomere 
length in PBMCs are contradictory with some reporting significant shortening (Engelhardt et 
al. 1998; Schröder et al. 2001) or no changes (Sanoff et al. 2014). A more recent investigation 
into the effects of chemotherapy on telomere length identified that treatment duration is 
linked to increased telomere shortening and that telomeres then lengthen in correlation to 
time after treatment (Benitez-Buelga et al. 2015). This suggests a recovery phase in which 
telomeres return to their original length (Benitez-Buelga et al. 2015) which may explain our 
study’s findings. A longitudinal study by Scuric et al. (2017) examined the differences in 
telomere length between breast cancer survivors who had received chemotherapy and/or 
radiotherapy and survivors who had surgery alone and reported no difference in telomere 
length between the groups three to six years after the completion of treatment (Scuric et al. 
2017). The majority of participants in the current study had either chemotherapy and/or 
radiotherapy so this makes it difficult to extrapolate the effect of the ACT intervention on 
telomere length especially in such a small sample size. 
Interleukin 6 (IL-6) is a biomarker of inflammation and has been previously shown to be 
decreased following psychotherapy interventions aimed at reducing stress in participants 
affected by illnesses other than cancer (Gallegos et al. 2015; Pullen et al. 2008)  however a 
study by Bower et al. (2014) found no significant change in IL-6 in response to a yoga-based 
mindfulness intervention in fatigued breast cancer survivors. The current study supported 
Bower et al. (2014)’s finding as it did not identify significant changes in IL-6 concentrations in 
response to ACT. The IL-6 concentrations of participants enrolled in the Bower et al (2014) 
study were lower than those found in this study’s participants however, this could be due to 
the effects of fatigue. The current study did not explicitly recruit participants who were 
experiencing fatigue, so this could account for the difference. The Pullen et al (2018) study 
reported a significant reduction in IL-6 concentrations in heart failure patients in response to 
the yoga intervention. The participants in the yoga trial had initial IL-6 concentrations similar 
to the average participant IL-6 concentrations in the current study however, the yoga trial 
only identified a significant decrease in IL-6 after a two month treatment period. This suggests 
that alterations in IL-6 from a mindfulness-based intervention may only be evident after a 
longer intervention. 
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Salivary cortisol is one of the most common molecular stress biomarkers that is measured in 
psychotherapy interventions. While the ACT intervention did not have a significant effect on 
waking salivary cortisol concentrations, a strong correlation was evident between cortisol 
concentration pre- and post-ACT intervention, indicating that measuring cortisol once in the 
morning resulted in consistent cortisol concentrations for individual participants. The average 
cortisol concentrations in the current study (7.47 ± 0.93 ng/mL, pre-ACT to 7.14 ± 0.92 ng/mL, 
post-ACT) were comparable to a study by Carlson et al. (2004), in which cancer patients had 
an average morning cortisol concentration of 6.34 (2.77) ng/mL (n = 31). The Carlson et al. 
(2004) study indicated that individual participants with higher average daily cortisol 
concentrations trend to a decrease in cortisol following the intervention whereas participants 
with lower average daily cortisol concentrations trend to an increase following the 
intervention (Carlson et al. 2004). This suggests that the effects of a mindfulness-based 
intervention (MBI) on cortisol concentrations depends on the individual’s pre-intervention 
concentrations.  Rather than use a single measurement on one day, the effects of stress on 
the hypothalamic-pituitary-adrenal (HPA) axis and cortisol concentrations may be better 
assessed by determining the diurnal cortisol rhythm or response to stress which would involve 
taking multiple cortisol measurements across the day. A more recent MBI study by Carlson et 
al. (2015) in distressed breast cancer survivors utilised the multiple cortisol measurement 
approach. It identified that participants had regular diurnal cortisol rhythms following the 
intervention compared to the control group, again indicating that multiple cortisol 
measurements throughout the day rather than a single measurement would be a more 
effective approach to measuring cortisol changes in response to a MBI (Carlson et al. 2015).  
Salivary alpha-amylase (sAA), a biomarker of sympathetic nervous system (SNS) activity, was 
previously shown to be reduced in cancer survivors following a MBI (Lipschitz et al. 2013). The 
current study did not find alterations in sAA concentrations in response to the ACT 
intervention. The sAA concentration changes in the current study (177.4 (146.9) U/mL pre-
ACT to 161.8 (127.0) U/mL) were higher than the Lipchitz et al. (2013) study (25 – 60 U/mL)   
and there was also a large variance in the current study compared to the Lipchitz et al. (2013) 
study. The large variance in sAA concentrations measured by the current study, indicated 
variance between individuals. This variance is potentially due to multiple factors that 
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influence the production of sAA including genetics, epigenetics and saliva collection technique 
(Beltzer et al. 2010; Sobas et al. 2016).  Although the current study did not find significant 
alterations in sAA concentrations in response to the ACT intervention, similar to the trends in 
cortisol there was a strong correlation between pre- and post-ACT sAA. 
Extensive research into the physiological responses to stress has linked individual 
physiological systems to health risks, yet little attention has been paid to the co-occurrence 
of physiological dysregulations across multiple systems (Seeman et al. 2010), the measure of 
cumulative allostatic load (AL) has aimed to address this limitation. Utilising a composite 
measure of AL may also potentially measure early pre-clinical signs of dysregulations across 
multiple systems (Seeman et al. 2010). The majority of research that incorporates an AL index 
utilise AL as a longitudinal predictive index in relation to health and cognitive outcomes 
throughout the lifespan, there are limited studies that assess the change in AL in response to 
an intervention. A study by Carlsson et al. (2017) determined the change in AL in response to 
the stress of workplace reorganisation (n = 359). This study used a measure of AL based on 
the original Seeman et al. (2001) ALI, with 13 biomarkers from four different systems 
(cardiovascular, metabolic, neuroendocrine and immune) and identified an increase in AL 
over the two-year study period (Carlsson et al. 2017). Ideally, an ALI would be calculated using 
biomarkers from a wide range of both primary mediators of stress responses and secondary 
outcome biomarkers. The current study explored the change in AL as measured by six 
biomarkers from four different systems. The biomarkers included: systolic and diastolic blood 
pressure, heart rate, fasting blood glucose, IL-6 and salivary cortisol. The ACT intervention 
resulted in varying effects on the AL for individuals with some having increased and others 
decreased ALs. As a cohort (n = 15) there was not a significant change in AL following the ACT 
intervention, but it was identified that Group 3 participants (n = 4) had a statistically 
significant positive change in allostatic load compared to both Group 1 (n = 7) and Group 2 (n 
= 4). The ACT intervention appeared to reduce the cumulative biological burden in the 
participants in Group 3, as measured by the change in AL. Due to circumstances beyond the 
control of the study team, the facilitator of Group 3’s ACT program was a different to Group 
1 and Group 2 who had the same facilitator. As Group 3 was the only group to demonstrate 
a significant and positive change in AL in response to the ACT intervention, the effect of the 
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facilitator is plausible. Previous studies have revealed a significant impact of therapist 
attributes and adherence to treatment manuals on patient outcomes in MBI and cognitive 
behavioural therapy interventions (Snippe et al. 2018; Zickgraf et al. 2016).  
The most obvious limitation of this study was the small sample size. This limited the power to 
discover statistically significant differences however, as a pilot study, this was expected. The 
other limitation was the number of confounding variables such as the variability in types and 
combinations of cancer treatments (chemotherapy, radiation and hormone therapy) 
undertaken by the participants, the contribution of lifestyle changes over the time of the 
study (such as diet and exercise) and the use of two different ACT facilitators. Furthermore, 
the inclusion of a wash-out period, such as a week of no intervention, could add strength and 
facilitate a clearer understanding of whether the six-week ACT program had an effect on the 
biomarkers.  
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Chapter 5: Conclusions and Future Directions 
In conclusion, this pilot study revealed that a six-week group-based ACT program could drive 
an improvement in AL but that this effect is highly variable. As the ACT intervention did not 
result in a consistent and significant change in physiological or molecular biomarkers, we can 
speculate that the participants in the study were not experiencing enough distress or the 
individual stress response systems were not dysregulated and therefore had no potential to 
improve.  
Improvements to a future trial could include a larger sample size, longer ACT intervention 
periods and a wash-out period between each intervention. In addition, recruiting participants 
with elevated physiological and molecular biomarkers could also be incorporated into the trial 
design. Finally, expanding the AL calculation by including additional biomarkers may further 
increase the value of this measure.  
In summary, although this pilot study did not demonstrate a significant improvement in 
physiological or molecular biomarkers of stress and AL in response to the group-based ACT 
intervention in all participants, it did demonstrate a significant improvement for some. The 
study also established a successful biomarker testing protocol in the study cohort.      
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Appendix B  
Hygienic collection of Saliva using the Salivette Cortisol device (Sarstedt 
51.1534.500) 
 
• The night before your Saturday morning session at the Hospital, label the 
Salivette Cortisol device with your date of birth. 
• As soon as you wake up on Saturday morning and before 
you get out of bed, remove the blue lid of Salivette 
Cortisol device to expose the swab material. 
• Place the cotton swab directly into mouth without touching 
with fingers. 
• Gently chew swab for about 60 seconds to produce saliva. 
• Then replace the swab directly into labelled tube (again, 
do not touch swab with fingers). 
• Replace the blue cap and seal securely. 
• Write the time and date of collection on the tube. 
• Place Salivette Cortisol device upright into the container provided and bring 
to your Saturday morning session at the Hospital. 
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Appendix C 
Table 4: Physiological and molecular biomarkers for each group at all four measurement 
time points. Mean and standard deviation calculated using all individual results at each 
time point are included. 
  Group 1 Group 2 Group 3 
  Time Point Time Point Time Point 
  1 2 3 4 1 2 3 4 1 2 3 4 
Heart Rate 
(bpm) 
N 7 7 6 7 5 6 6 5 6 5 5 6 
Mean  
(SD) 
70.29 
(6.42) 
70.86 
(6.77) 
70.00 
(4.94) 
73.43 
(8.87) 
73.40 
(13.24) 
71.67 
(10.25) 
73.33 
(7.31) 
76.80 
(18.67) 
67.33 
(9.33) 
69.40 
(10.74) 
71.00 
(10.79) 
70.17 
(10.42) 
Minimum 
Maximum 
61 
79 
62 
79 
64 
78 
62 
87 
55 
90 
55 
82 
65 
85 
62 
107 
60 
85 
57 
86 
56 
82 
57 
88 
Systolic 
Blood 
Pressure 
(mmHg) 
N 7 7 6 7 4 5 5 4 6 5 5 6 
Mean  
(SD) 
130.57 
(8.52) 
125.14 
(11.01) 
115.33 
(9.77) 
120.57 
(11.41) 
133.50 
(8.18) 
117.20 
(18.31) 
119.20 
(13.31) 
114.00 
(14.54) 
132.00 
(11.37) 
120.00 
(17.50) 
122.00 
(8.00) 
117.33 
(12.50) 
Minimum 
Maximum 
119 
143 
108 
138 
100 
128 
98 
130 
121 
140 
92 
138 
108 
138 
100 
131 
112 
143 
92 
134 
114 
134 
98 
132 
Diastolic 
Blood 
Pressure 
(mmHg) 
N 7 7 6 7 4 5 5 4 6 5 5 6 
Mean  
(SD) 
84.29 
(5.56) 
83.14 
(9.58) 
73.00 
(4.15) 
79.14 
(4.18) 
88.50 
(9.00) 
76.40 
(10.04) 
77.60 
(9.63) 
78.25 
(5.85) 
85.00 
(10.92) 
78.60 
(10.04) 
74.00 
(8.60) 
75.83 
(10.13) 
Minimum 
Maximum 
76 
92 
68 
94 
68 
78 
75 
88 
76 
96 
64 
88 
68 
88 
72 
85 
68 
96 
67 
90 
66 
86 
60 
90 
Blood 
Glucose 
(mmol/L) 
N 7 7 6 7 4 6 5 5 6 5 5 6 
Mean  
(SD) 
5.03 
(0.63) 
5.54 
(0.67) 
5.62 
(0.53) 
5.54 
(0.52) 
4.93 
(0.43) 
5.77 
(0.78) 
5.72 
(0.40) 
5.66 
(0.41) 
5.07 
(0.42) 
5.32 
(0.51) 
5.16 
(0.18) 
5.32 
(0.40) 
Minimum 
Maximum 
4.1  
5.9 
4.6 
6.6 
4.8 
6.3 
4.8 
6.2 
4.3 
5.2 
5.1 
7.3 
5.3 
6.3 
5.2 
6.2 
4.3 
5.5 
4.7 
6.0 
5.0 
5.4 
4.9 
5.9 
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Table 4 Continued: Physiological and molecular biomarkers for each group at all four 
measurement time points. Mean and standard deviation calculated using all individual 
results at each time point are included. 
  Group 1 Group 2 Group 3 
  Time Point Time Point Time Point 
  1 2 3 4 1 2 3 4 1 2 3 4 
Relative 
Telomere 
Length 
N 6 6 5 5 4 5 5 5 6 5 5 5 
Mean  
(SD) 
1.64 
(0.51) 
1.62 
(0.37) 
1.53 
(0.13) 
1.83 
(0.94) 
1.60 
(0.46) 
1.61 
(0.43) 
1.69 
(0.23) 
2.04 
(1.05) 
1.63 
(0.63) 
1.67 
(0.39) 
1.48 
(0.42) 
2.01 
(1.00) 
Minimum 
Maximu
m 
1.15 
2.54 
1.17 
2.23 
1.33 
1.67 
0.54 
2.76 
1.31 
2.28 
1.19 
2.33 
1.47 
2.03 
0.57 
3.36 
0.89 
2.67 
1.17 
2.13 
1.08 
2.13 
0.27 
2.82 
Interleukin 6 
(pg/mL)  
N 6 6 5 5 4 5 5 5 6 5 5 5 
Mean  
(SD) 
2.98 
(1.81) 
4.44 
(2.85) 
4.45 
(2.04) 
2.72 
(1.69) 
3.12 
(1.65) 
2.96 
(3.00) 
2.64 
(1.43) 
2.21 
(2.31) 
5.52 
(1.46) 
6.91 
(4.20) 
4.29 
(1.67) 
3.60 
(1.28) 
Minimum 
Maximu
m 
0.14 
5.29 
0.00 
8.48 
1.48 
6.92 
0.14 
4.20 
1.17 
4.95 
0.57 
7.31 
0.78 
4.36 
0.00 
5.76 
3.50 
6.74 
1.94 
12.60 
1.58 
6.17 
1.36 
4.43 
Cortisol 
(ng/mL) 
N 5 6 5 5 4 4 4 3 5 5 4 6 
Mean  
(SD) 
8.11 
(3.92) 
6.94 
(3.64) 
7.46 
(3.72) 
9.72 
(9.90) 
6.94 
(3.11) 
7.06 
(4.68) 
7.64 
(3.65) 
6.20 
(1.20) 
8.03 
(3.98) 
6.80 
(1.26) 
6.47 
(3.01) 
9.32 
(6.38) 
Minimum 
Maximu
m 
4.47 
12.62 
4.19 
13.08 
4.49 
13.85 
4.12 
27.35 
4.09 
10.89 
3.84 
13.78 
4.25 
11.00 
4.93 
7.32 
5.16 
14.95 
5.72 
8.81 
2.39 
9.64 
4.09 
21.65 
Salivary 
Alpha 
Amylase 
(U/mL) 
N 6 6 5 5 5 5 5 4 6 5 4 6 
Mean  
(SD) 
223.88 
(137.22) 
137.76 
(79.80) 
168.12 
(39.08) 
176.96 
(124.26) 
82.03 
(86.17) 
179.69 
(187.79) 
190.61 
(165.38) 
110.55 
(80.93) 
86.12 
(71.07) 
119.75 
(96.88) 
161.98 
(160.16) 
150.91 
(159.58
) 
Minimum 
Maximu
m 
95.04 
490.45 
60.69 
287.31 
143.12 
236.52 
56.83 
376.55 
15.96 
213.79 
6.05 
462.88 
19.35 
389.58 
23.94 
206.05 
0.00 
216.21 
12.10 
247.65 
9.23 
355.02 
7.18 
377.76 
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Appendix D 
Table 5: Physiological and molecular biomarkers for each group at time points T1, T2 and 
T3. Mean and SEM are calculated for each biomarker and each group separately to include 
individuals with all three time point measurements. Bold values indicate significant 
difference (p < 0.05) between time points within one group. Time points with different 
superscripts within a biomarker for one group identify significance (p < 0.05) between time 
points. No superscripts indicate no significant differences (p > 0.05).   
    
Group 1 (ACT - BCE) Group 2 (BCE - ACT) 
Group 3 (Waitlist - 
ACT) 
    Time Point Time Point Time Point 
    1 2 3 1 2 3 1 2 3 
Heart Rate 
(bpm) 
N 6 6 6 5 5 5 3 3 3 
Mean 
(SEM) 
70.00 
(2.85) 
70.67 
(3.02) 
70.00 
(2.02) 
73.40 
(5.92) 
69.80 
(4.59) 
72.40 
(3.47) 
70.00 
(7.64) 
70.67 
(8.41) 
69.00 
(7.51) 
Systolic 
Blood 
Pressure 
(mmHg) 
N 6 6 6 4 4 4 3 3 3 
Mean 
(SEM) 
130.00a 
(3.75) 
124.00ab 
(4.73) 
115.33b 
(3.99) 
132.50 
(4.09) 
118.50 
(10.44) 
122.00 
(6.78) 
136.33 
(2.96) 
126.67 
(6.36) 
126.00 
(4.62) 
Diastolic 
Blood 
Pressure 
(mmHg) 
N 6 6 6 4 4 4 3 3 3 
Mean 
(SEM) 
84.83a 
(2.40) 
83.00ab 
(4.28) 
73.00b 
(1.69) 
88.50 
(4.50) 
78.50 
(5.12) 
79.00 
(5.26) 
92.00 
(2.00) 
84.67 
(4.37) 
78.67 
(4.67) 
Blood 
Glucose 
(mmol/L) 
N 6 6 6 4 4 4 3 3 3 
Mean 
(SEM) 
4.98a 
(0.27) 
5.55b 
(0.30) 
5.62b 
(0.22) 
4.93a 
(0.21) 
5.40ab 
(0.12) 
5.70b 
(0.23) 
5.10 
(0.10) 
5.30 
(0.17) 
5.23 
(0.12) 
Relative 
Telomere 
Length 
N 5 5 5 4 4 4 3 3 3 
Mean 
(SEM) 
1.58 
(0.25) 
1.50 
(0.11) 
1.53 
(0.06) 
1.60 
(0.23) 
1.63 
(0.25) 
1.74 
(0.11) 
1.26 
(0.28) 
1.56 
(0.25) 
1.29 
(0.18) 
Interleukin-
6 (pg/mL)  
N 5 5 5 4 4 4 3 3 3 
Mean 
(SEM) 
3.54 
(0.58) 
4.48 
(1.42) 
4.45 
(0.91) 
3.12 
(0.82) 
3.55 
(1.55) 
2.83 
(0.79) 
5.34 
(0.92) 
9.60 
(1.55) 
5.06 
(0.55) 
Cortisol 
(ng/mL) 
N 4 4 4 4 4 4 3 3 3 
Mean 
(SEM) 
6.98 
(1.73) 
5.81 
(1.32) 
7.83 
(2.09) 
6.94 
(1.56) 
7.06 
(2.34) 
7.64 
(1.83) 
5.85a 
(0.44) 
7.42b 
(0.75) 
6.28ab 
(2.11) 
Salivary 
Alpha 
Amylase 
(U/mL) 
N 5 5 5 5 5 5 4 4 4 
Mean 
(SEM) 
224.65 
(68.60) 
153.18 
(35.15) 
168.12 
(17.48) 
82.03 
(38.53) 
179.69 
(83.98) 
190.61 
(73.96) 
86.94 
(45.86) 
104.84 
(52.52) 
161.98 
(80.08) 
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